<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006050.pub2" GROUP_ID="NEUROMUSC" ID="345105021509502431" MERGED_FROM="" MODIFIED="2013-04-03 14:36:34 +0100" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;/p&gt;" NOTES_MODIFIED="2013-03-04 15:18:39 +0000" NOTES_MODIFIED_BY="Ruth Brassington" REVIEW_NO="101" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2013-04-03 14:36:34 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE>Immunosuppressive treatment for non-systemic vasculitic neuropathy</TITLE>
<CONTACT MODIFIED="2013-04-03 14:36:34 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="15458" ROLE="AUTHOR"><FIRST_NAME>Alexander</FIRST_NAME><MIDDLE_INITIALS>FJE</MIDDLE_INITIALS><LAST_NAME>Vrancken</LAST_NAME><POSITION>MD PhD</POSITION><EMAIL_1>a.f.j.e.vrancken@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>Rudolf Magnus Institute for Neuroscience</ADDRESS_1><CITY>Utrecht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 7555555</PHONE_1><PHONE_2>+31 88 7551882</PHONE_2><FAX_1>+31 88 7552100</FAX_1><FAX_2>+31 88 7555505</FAX_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-04-03 14:36:34 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="15458" ROLE="AUTHOR"><FIRST_NAME>Alexander</FIRST_NAME><MIDDLE_INITIALS>FJE</MIDDLE_INITIALS><LAST_NAME>Vrancken</LAST_NAME><POSITION>MD PhD</POSITION><EMAIL_1>a.f.j.e.vrancken@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>Rudolf Magnus Institute for Neuroscience</ADDRESS_1><CITY>Utrecht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 7555555</PHONE_1><PHONE_2>+31 88 7551882</PHONE_2><FAX_1>+31 88 7552100</FAX_1><FAX_2>+31 88 7555505</FAX_2></ADDRESS></PERSON><PERSON ID="7655" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>AC</MIDDLE_INITIALS><LAST_NAME>Hughes</LAST_NAME><SUFFIX>MD FRCP FMedSci</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>rhughes11@btinternet.com</EMAIL_1><ADDRESS><DEPARTMENT>MRC Centre for Neuromuscular Diseases</DEPARTMENT><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1>PO Box 114</ADDRESS_1><ADDRESS_2>Queen Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7676 2060</PHONE_1><FAX_1>+44 20 7829 8725</FAX_1></ADDRESS></PERSON><PERSON ID="E322B37382E26AA201E74FE9DA430401" ROLE="AUTHOR"><FIRST_NAME>Gérard</FIRST_NAME><LAST_NAME>Said</LAST_NAME><SUFFIX>MD PhD</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>grrdsd@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Service de Neurologie</DEPARTMENT><ORGANISATION>Centre Hospitalier Universitaire de Bicêtre (Université Paris XI)</ORGANISATION><ADDRESS_1>Rue du Général Leclerc</ADDRESS_1><ADDRESS_2>Hôpital de Bicêtre</ADDRESS_2><CITY>Le Kremlin-Bicêtre, Paris</CITY><ZIP>94275</ZIP><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+ 33 1 4521 2628</PHONE_1><FAX_1>+ 33 1 4521 2853</FAX_1></ADDRESS></PERSON><PERSON ID="15464" ROLE="AUTHOR"><FIRST_NAME>John</FIRST_NAME><MIDDLE_INITIALS>HJ</MIDDLE_INITIALS><LAST_NAME>Wokke</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Chairman</POSITION><EMAIL_1>j.wokke@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>Rudolf Magnus Institute of Neuroscience</ADDRESS_1><CITY>Utrecht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 88 7556564</PHONE_1><FAX_1>+ 31 30 2542100</FAX_1></ADDRESS></PERSON><PERSON ID="15421" ROLE="AUTHOR"><FIRST_NAME>Nicolette</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Notermans</LAST_NAME><POSITION>MD PhD</POSITION><EMAIL_1>n.c.notermans@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>Rudolf Magnus Institute for Neuroscience</ADDRESS_1><CITY>Utrecht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 2509111</PHONE_1><FAX_1>+31 30 2542100</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-03-04 15:18:39 +0000" MODIFIED_BY="Ruth Brassington">
<UP_TO_DATE>
<DATE DAY="17" MONTH="3" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="3" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="3" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2013-03-04 15:18:29 +0000" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-03-04 15:18:29 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="4" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>Added <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK> on the date of the next update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-03-04 15:17:54 +0000" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-03-04 15:17:54 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="25" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>Searches updated to March 2011. No relevant trials were identified for inclusion. Text of review was edited, and references were updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-06-29 12:12:24 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="5" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Searches updated to April 2009. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-05 12:00:31 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="14" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-07-16 23:40:41 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="9" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-11-10 17:27:13 +0000" MODIFIED_BY="Ruth Brassington">
<INTERNAL_SOURCES MODIFIED="2009-11-10 17:27:13 +0000" MODIFIED_BY="Ruth Brassington">
<SOURCE>
<NAME>The Rudolf Magnus Institute for Neuroscience, University Medical Centre Utrecht, Department of Neurology and Neuromuscular Diseases</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>King's College London School of Medicine, London, Department of Clinical Neuroscience</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-11-10 17:27:13 +0000" MODIFIED_BY="Ruth Brassington">
<NAME>Cochrane Neuromuscular Disease Group, National Hospital for Neurology and Neurosurgery</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Centre Hospitalier Universitaire de Bicêtre, Université Paris XI, Service de Neurologie, Le Kremlin-Bicêtre, Paris</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-03-04 15:17:42 +0000" MODIFIED_BY="Ruth Brassington">
<SUMMARY MODIFIED="2011-07-06 14:47:36 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2009-11-10 16:57:24 +0000" MODIFIED_BY="Ruth Brassington">Treatments that suppress the immune system for neuropathy caused by non-systemic vasculitis (inflammation of blood vessels limited to those supplying the peripheral nerves)</TITLE>
<SUMMARY_BODY MODIFIED="2011-07-06 14:47:36 +0100" MODIFIED_BY="Ruth Brassington">
<P>Non-systemic vasculitic neuropathy ('isolated vasculitic neuropathy') is a rare disease causing progressive, disabling, painful loss of sensation with muscle weakness in arms and legs that is often asymmetrical. The diagnosis is made through the finding of inflammation of blood vessels confined to nerve or muscle tissue, or both, and by excluding other conditions that could be the cause, such as systemic vasculitis (inflammation of blood vessels affecting multiple organs in the body), rheumatic diseases, or any other cause for the neuropathy. This is an updated review. No randomised controlled clinical trials have been performed on which to base immunosuppressive treatment for non-systemic vasculitic neuropathy. Blinded randomised trials of adding other immunosuppressive agents to corticosteroids are needed. Such trials will need sufficiently long follow-up periods to evaluate treatment efficacy with disability outcome measures designed and validated for assessing change in immune-mediated inflammatory neuropathies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-07-06 14:47:27 +0100" MODIFIED_BY="Ruth Brassington">
<ABS_BACKGROUND MODIFIED="2011-06-29 11:31:46 +0100" MODIFIED_BY="Ruth Brassington">
<P>Non-systemic vasculitic neuropathy is a rare disabling disease that usually has a subacute onset of progressive or relapsing-remitting sensory or sensorimotor deficits. Asymmetry, pain and weakness are key features. The diagnosis can only be made by exclusion of other causes, the absence of systemic vasculitis or other rheumatic diseases, and the demonstration of vasculitis in a nerve or a combined nerve and muscle biopsy. There is a need for efficacious therapy to prevent disease progression and improve prognosis. This is an updated review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-04-08 12:31:22 +0100" MODIFIED_BY="[Empty name]">
<P>To assess if immunosuppressive treatment in non-systemic vasculitic neuropathy reduces disability, and ameliorates neurological symptoms, and if such therapy can be given safely.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-07-06 14:46:42 +0100" MODIFIED_BY="Ruth Brassington">
<P>The Cochrane Neuromuscular Disease Group Specialized Register was searched again in May 2011, The Cochrane Central Register of Controlled Trials<I> </I>CENTRAL in <I>The Cochrane Library</I>, Pubmed, EMBASE and Web of Science/ISI Web of Knowledge were searched again in March 2011. Because non-systemic vascular neuropathy was first recognised in the 1980s, the searches were done from January 1980 onwards. In addition, the reference lists of retrieved articles relevant to and cited in this review were handsearched.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-09-02 14:48:22 +0100" MODIFIED_BY="Ruth Brassington">
<P>All randomised or quasi-randomised trials that examined the efficacy of immunosuppressive treatment for non-systemic vasculitic neuropathy at least one year after the onset of therapy were sought. Participants had to fulfil the following criteria: absence of systemic or neurological disease, exclusion of any recognised cause of the neuropathy by appropriate clinical or laboratory investigations, electrophysiological studies in agreement with axonal neuropathy, confirmation of vasculitis in a nerve or a combined nerve and muscle biopsy. The primary outcome was to be improvement in disability. Secondary outcomes were to be change in the mean disability score, change in muscle strength measured with the Medical Research Council sum score, change in pain or other positive sensory symptoms, number of relapses, and adverse events.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-07-06 14:47:27 +0100" MODIFIED_BY="Ruth Brassington">
<P>Two authors independently reviewed and extracted details of all potentially relevant trials. For included studies pooled risk ratios and pooled standardised mean differences were to be calculated to assess treatment efficacy.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-05-15 13:26:10 +0100" MODIFIED_BY="[Empty name]">
<P>Thirty studies were identified and assessed for possible inclusion in the review, but all were excluded because of insufficient quality or lack of relevance.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-09-02 14:48:14 +0100" MODIFIED_BY="Ruth Brassington">
<P>No adequate randomised or quasi-randomised controlled trials have been performed on which to base treatment for non-systemic vasculitic neuropathy. Randomised trials are needed, especially of adding other immunosuppressive agents to corticosteroids. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-07-06 15:00:22 +0100" MODIFIED_BY="Ruth Brassington">
<BACKGROUND MODIFIED="2011-07-06 15:00:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>Vasculitis (inflammation of blood vessels) is an uncommon cause of peripheral neuropathy. The incidence and prevalence of vasculitic neuropathy are unknown, but in consecutive neuromuscular biopsy studies vasculitis is found in about one per cent of biopsied cases per year irrespective of biopsy indication (<LINK REF="STD-Davies-1996" TYPE="STUDY">Davies 1996</LINK>; <LINK REF="REF-Deprez-2000" TYPE="REFERENCE">Deprez 2000</LINK>; <LINK REF="STD-Kararizou-2005" TYPE="STUDY">Kararizou 2005</LINK>; <LINK REF="STD-Kissel-1985" TYPE="STUDY">Kissel 1985</LINK>; <LINK REF="REF-Oh-1990" TYPE="REFERENCE">Oh 1990</LINK>; <LINK REF="STD-Prayson-2003" TYPE="STUDY">Prayson 2003</LINK>), and in about one-third of cases suspected of vasculitic neuropathy (<LINK REF="REF-Claussen-2000" TYPE="REFERENCE">Claussen 2000</LINK>; <LINK REF="REF-Collins-2000" TYPE="REFERENCE">Collins 2000</LINK>; <LINK REF="REF-Vital-2006" TYPE="REFERENCE">Vital 2006</LINK>). Vasculitic neuropathy occurs in the setting of systemic vasculitis and connective tissue disease (<LINK REF="REF-Cattaneo-2007" TYPE="REFERENCE">Cattaneo 2007</LINK>; <LINK REF="REF-Pagnoux-2004" TYPE="REFERENCE">Pagnoux 2004</LINK>; <LINK REF="REF-Rosenbaum-2001" TYPE="REFERENCE">Rosenbaum 2001</LINK>; <LINK REF="REF-Said-2005" TYPE="REFERENCE">Said 2005</LINK>; <LINK REF="REF-Vital-2006" TYPE="REFERENCE">Vital 2006</LINK>), sarcoidosis (<LINK REF="REF-Said-2002" TYPE="REFERENCE">Said 2002</LINK>; <LINK REF="REF-Vital-2008" TYPE="REFERENCE">Vital 2008</LINK>), malignancy (<LINK REF="REF-Fain-2007" TYPE="REFERENCE">Fain 2007</LINK>; <LINK REF="REF-Oh-1997" TYPE="REFERENCE">Oh 1997</LINK>; <LINK REF="STD-Zivkovic-2007" TYPE="STUDY">Zivkovic 2007</LINK>), infectious disease (<LINK REF="REF-Nemni-2003" TYPE="REFERENCE">Nemni 2003</LINK>; <LINK REF="REF-Said-2007" TYPE="REFERENCE">Said 2007</LINK>), or can be drug-induced (<LINK REF="REF-Wiik-2008" TYPE="REFERENCE">Wiik 2008</LINK>). Vasculitic neuropathy is sometimes a presenting or early manifestation of systemic disease (<LINK REF="REF-Bourgarit-2005" TYPE="REFERENCE">Bourgarit 2005</LINK>; <LINK REF="REF-Cattaneo-2007" TYPE="REFERENCE">Cattaneo 2007</LINK>; <LINK REF="REF-Agard-2003" TYPE="REFERENCE">Agard 2003</LINK>; <LINK REF="REF-de-Groot-2001" TYPE="REFERENCE">de Groot 2001</LINK>). Some people with vasculitic neuropathy appear to have vasculitis restricted to the peripheral nerves or adjacent muscles upon biopsy (<LINK REF="REF-Collins-2000" TYPE="REFERENCE">Collins 2000</LINK>; <LINK REF="REF-Said-2005" TYPE="REFERENCE">Said 2005</LINK>; <LINK REF="REF-Vital-2006" TYPE="REFERENCE">Vital 2006</LINK>). In the absence of other causes for the neuropathy this has been called non-systemic vasculitic neuropathy or isolated vasculitis of the peripheral nervous system (<LINK REF="STD-Collins-2003" TYPE="STUDY">Collins 2003</LINK>; <LINK REF="STD-Davies-1996" TYPE="STUDY">Davies 1996</LINK>; <LINK REF="STD-Dyck-1987" TYPE="STUDY">Dyck 1987</LINK>; <LINK REF="STD-Kissel-1985" TYPE="STUDY">Kissel 1985</LINK>; <LINK REF="REF-Schaublin-2005" TYPE="REFERENCE">Schaublin 2005</LINK>).</P>
<P>Except for the presence of multi-organ involvement and prognosis, the clinical and pathological features in non-systemic vasculitic neuropathy (NSVN) are indistinguishable from those in systemic vasculitic neuropathy (<LINK REF="REF-Collins-2010" TYPE="REFERENCE">Collins 2010</LINK>). Women are more often affected than men (about 60% versus 40%) and the average age at diagnosis is about 60 years. Characteristically there is a subacute onset of progressive or relapsing sensory or sensorimotor deficits involving one or multiple nerves. However, a less abrupt onset of a more or less symmetric progressive polyneuropathy with occasional relapses of asymmetric focal neurological deficits does occur. Pain and predominantly somatic sensory disturbances in the limbs, usually accompanied by weakness and atrophy, constitute the main neurological symptoms. Cranial neuropathy, lumbosacral polyradiculoneuropathy, pure sensory or small fibre neuropathy occur occasionally (<LINK REF="STD-Collins-2003" TYPE="STUDY">Collins 2003</LINK>; <LINK REF="STD-Dyck-1987" TYPE="STUDY">Dyck 1987</LINK>; <LINK REF="REF-Lacomis-1997" TYPE="REFERENCE">Lacomis 1997</LINK>; <LINK REF="REF-Molyneux-2000" TYPE="REFERENCE">Molyneux 2000</LINK>; <LINK REF="STD-Seo-JH-2004" TYPE="STUDY">Seo JH 2004</LINK>; <LINK REF="REF-Tsunemi-1999" TYPE="REFERENCE">Tsunemi 1999</LINK>).</P>
<P>Electrophysiological studies invariably show an axonal neuropathy in a multifocal or generalised pattern, and the findings are often more extensive than suspected on clinical grounds (<LINK REF="REF-Claussen-2000" TYPE="REFERENCE">Claussen 2000</LINK>; <LINK REF="REF-Collins-2000" TYPE="REFERENCE">Collins 2000</LINK>; <LINK REF="STD-Dyck-1987" TYPE="STUDY">Dyck 1987</LINK>; <LINK REF="REF-Pavesi-1987" TYPE="REFERENCE">Pavesi 1987</LINK>; <LINK REF="STD-Seo-JH-2004" TYPE="STUDY">Seo JH 2004</LINK>). Transient distal but not proximal nerve excitability that resembles conduction block (so called 'pseudo conduction block'), but without concomitant slowing of nerve conduction velocity or other evidence of demyelination may also be present. This finding reflects ongoing Wallerian degeneration and axonal damage caused by focal ischaemic nerve injury from vasculitic lesions (<LINK REF="REF-Fujimura-1991" TYPE="REFERENCE">Fujimura 1991</LINK>; <LINK REF="REF-Kuntzer-1995" TYPE="REFERENCE">Kuntzer 1995</LINK>; <LINK REF="REF-McCluskey-1999" TYPE="REFERENCE">McCluskey 1999</LINK>; <LINK REF="REF-Ropert-1990" TYPE="REFERENCE">Ropert 1990</LINK>).</P>
<P>The diagnosis of NSVN should only be made in the absence of other causes of the neuropathy. Thus, any metabolic, endocrine or infectious disease, malignancy, paraproteinaemia, and cryoglobulinaemia should be ruled out as well as systemic vasculitis or rheumatic diseases for which classification criteria exist. Ultimately the diagnosis depends on the demonstration of characteristic inflammatory vascular lesions in nerve or muscle tissue, or both, but without evidence of multi-organ involvement (<LINK REF="REF-Collins-2010" TYPE="REFERENCE">Collins 2010</LINK>). Combined nerve and muscle biopsy moderately improves the diagnostic yield by 5 to 15% (<LINK REF="REF-Vrancken-2011" TYPE="REFERENCE">Vrancken 2011</LINK>). The pathological definition of vasculitis is the presence of inflammation or necrosis of an arterial blood vessel wall by transmural infiltration with inflammatory cells, usually with vessel lumen obstruction. The most commonly affected blood vessels are located in the epineurium. The inflammatory lesions are segmentally localised along blood vessels ('skip lesions') and can be very small or involve very small calibre vessels only (<LINK REF="REF-Collins-2000" TYPE="REFERENCE">Collins 2000</LINK>; <LINK REF="REF-Dyck-1972" TYPE="REFERENCE">Dyck 1972</LINK>; <LINK REF="STD-Said-1988" TYPE="STUDY">Said 1988</LINK>; <LINK REF="STD-Sugiura-2006" TYPE="STUDY">Sugiura 2006</LINK>; <LINK REF="REF-Vital-2006" TYPE="REFERENCE">Vital 2006</LINK>; <LINK REF="STD-Vrancken-2004" TYPE="STUDY">Vrancken 2004</LINK>). Vascular inflammation without clear vessel wall damage but with vasculitis-associated signs of ischaemic injury such as large variability in the degree of axonal degeneration between nerve fascicles or iron depositions may support the diagnosis ('probable' vasculitis) (<LINK REF="REF-Collins-2010" TYPE="REFERENCE">Collins 2010</LINK>).</P>
<P>Although disease-related mortality and morbidity are higher than in the general population, NSVN carries a better prognosis than systemic vasculitic neuropathy (<LINK REF="STD-Collins-2003" TYPE="STUDY">Collins 2003</LINK>; <LINK REF="STD-Davies-1996" TYPE="STUDY">Davies 1996</LINK>; <LINK REF="STD-Dyck-1987" TYPE="STUDY">Dyck 1987</LINK>; <LINK REF="STD-Mathew-2007" TYPE="STUDY">Mathew 2007</LINK>; <LINK REF="STD-Sugiura-2006" TYPE="STUDY">Sugiura 2006</LINK>). Moreover, there are isolated reports of people with NSVN who were not treated but showed no progression and spontaneous remission (<LINK REF="REF-Behari-1995" TYPE="REFERENCE">Behari 1995</LINK>; <LINK REF="REF-De-la-Sayette-1995" TYPE="REFERENCE">De la Sayette 1995</LINK>; <LINK REF="REF-Larrod_x00e9_-1997" TYPE="REFERENCE">Larrodé 1997</LINK>; <LINK REF="STD-Mathew-2007" TYPE="STUDY">Mathew 2007</LINK>; <LINK REF="STD-Seo-JH-2004" TYPE="STUDY">Seo JH 2004</LINK>; <LINK REF="STD-Sobue-1989" TYPE="STUDY">Sobue 1989</LINK>). Nevertheless, NSVN usually runs a progressive course and the increasing severity of neurological deficits may cause considerable disability. At the time of preparing this review diverse therapeutic strategies for NSVN had been proposed that invariably included corticosteroids (<LINK REF="STD-Collins-2003" TYPE="STUDY">Collins 2003</LINK>; <LINK REF="STD-Davies-1996" TYPE="STUDY">Davies 1996</LINK>; <LINK REF="REF-Gorson-2006" TYPE="REFERENCE">Gorson 2006</LINK>; <LINK REF="REF-Heuss-2003" TYPE="REFERENCE">Heuss 2003</LINK>; <LINK REF="REF-Pagnoux-2004" TYPE="REFERENCE">Pagnoux 2004</LINK>; <LINK REF="REF-Schaublin-2005" TYPE="REFERENCE">Schaublin 2005</LINK>). No randomised controlled trials for the treatment of NSVN were known to have been published, but without an exhaustive search it would be inappropriate to conclude that none have been done. Nevertheless, there is going to be a need for such trials and a prior systematic review was necessary to ascertain that no trials had been done, and also to reveal treatment options worth attempting. This review provides a systematic analysis of randomised trials of immunosuppressive treatment for NSVN. Since no such trials were found, the efficacy of immunosuppressive therapy in consecutive patient series and of randomised trials in other types of vasculitis, many of which may involve the peripheral nervous system, have been evaluated in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section of the review.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To provide the best available evidence from randomised controlled trials on the role of immunosuppressive agents in treating NSVN.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-07-06 15:00:18 +0100" MODIFIED_BY="Ruth Brassington">
<SELECTION_CRITERIA MODIFIED="2011-07-06 15:00:05 +0100" MODIFIED_BY="Ruth Brassington">
<CRIT_STUDIES>
<P>All properly randomised or quasi-randomised (alternate or other systematic treatment allocation) trials examining the effects of immunosuppressive treatment for NSVN.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-09-02 14:46:37 +0100" MODIFIED_BY="Ruth Brassington">
<P>Eligible studies had to include participants of any age with NSVN, i.e. symptoms and signs of neuropathy with an electrophysiological diagnosis of axonal neuropathy. The clinical manifestations should not be explained by other neurological diseases, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or any other demyelinating neuropathy. Extensive history taking, and clinical and laboratory investigations should have been performed to exclude any recognised cause of the neuropathy such as diabetes mellitus, renal insufficiency, biliary cirrhosis, alcohol abuse, medication use, toxic substance exposure, thyroid disorder, vitamin deficiency, malignancy, infectious disease (e.g. HIV, hepatitis B, leprosy), polycythaemia, paraprotein, systemic vasculitis, autoimmune or connective tissue disease, inflammatory bowel disease, metabolic storage disease, sarcoidosis and amyloidosis. A nerve biopsy or a combined muscle and nerve biopsy was mandatory in each participant to establish a definite or probable diagnosis of vasculitis based on clearly predefined pathological criteria by the authors. 'Definite' vasculitis should have been defined as the presence of vascular inflammation with leukocytoclasis or with any of the following signs of vascular damage: fibrinoid necrosis, fragmentation/loss of smooth muscle cells in the tunica media, endothelial cells, or lamina elastica interna, hyperplasia/fibrosis of the tunica media or intima, vessel lumen occlusion by acute or chronic thrombosis with or without recanalisation. 'Probable' vasculitis should have been defined as the presence of (peri)vascular inflammation without clear evidence of vessel wall damage, but accompanied by one or more additional signs of ischaemic injury such as asymmetrical axonal degeneration or nerve fibre loss within or between nerve fascicles, iron/haemosiderin deposits, neovascularisation.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any immunosuppressive treatment (including corticosteroids, plasma exchange and intravenous immunoglobulin) alone or in combination versus placebo or another immunosuppressive treatment ('head-to-head' comparison study design), with no restrictions to the route of administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-07-06 15:00:05 +0100" MODIFIED_BY="Ruth Brassington">
<P>The primary outcome was improvement in disability as determined by the original authors at least one year after the onset of treatment. Where possible, disability data were to be transformed to a modified Rankin scale (<LINK REF="REF-Merkies-2003" TYPE="REFERENCE">Merkies 2003</LINK>):<BR/>0 = Healthy, asymptomatic.<BR/>1 = Non-disabling symptoms that do not interfere with daily activities.<BR/>2 = Minor disabling symptoms that lead to some interference with daily activities, self-supportive, occasional use of walking aids such as ankle foot orthoses, walking stick or walking frame.<BR/>3 = Moderate disabling symptoms significantly interfering with daily activities or preventing totally independent existence, frequent use of walking aids.<BR/>4 = Severe disabling symptoms clearly preventing independent existence but not requiring constant care taking, only ambulant with walking aids.<BR/>5 = Completely disabled and totally dependent requiring constant care taking, not ambulant.<BR/>If necessary, authors were to be asked for the original data to enable this transformation. Improvement was defined as at least one point decrease on this Rankin scale. Unchanged or increased scoring on the Rankin scale was considered as no improvement.</P>
<P>Secondary outcomes (assessed at least one year after the onset of treatment and compared to baseline) were:<BR/>(1) Change in disability score as used by the original authors expressed as standardised mean difference. Where possible, disability data would be transformed to the modified Rankin scale as described above;<BR/>(2) Change in MRC sum score (<LINK REF="REF-Merkies-2003" TYPE="REFERENCE">Merkies 2003</LINK>) expressed as standardised mean difference (the MRC sum score as most commonly used, ranges from 0 being completely paralysed to 60 being normal);<BR/>(3) Change in pain or other positive sensory symptoms;<BR/>(4) Number of relapses as defined by the original authors;<BR/>(5) Adverse events separated into severe (life-threatening, requiring or lengthening hospitalisation, or fatal) and others.</P>
<P>If necessary for the meta-analysis, the results using the primary or secondary outcome measures from studies with different follow-up periods were to be appropriately re-scaled on the assumption of constant rates of change.</P>
<P>If randomised trials had been found we would have prepared a 'Summary of findings' table reporting the primary outcome, change in MRC sum score and adverse events.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-07-06 14:50:13 +0100" MODIFIED_BY="Ruth Brassington">
<P>In this updated review we searched the Cochrane Neuromuscular Disease Group Trials Register (3 May 2011), The Cochrane Central Register of Controlled Trials CENTRAL (Issue 1, 2011 in <I>The Cochrane Library</I>) , Pubmed MEDLINE (January 1980 to 17 March 2011), EMBASE (January 1980 to 17 March 2011), and Web of Science/ISI Web of Knowledge (January 1980 to 17 March 2011). The authors performed the searches. Because NSVN was first recognised in the 1980s (<LINK REF="STD-Dyck-1987" TYPE="STUDY">Dyck 1987</LINK>; <LINK REF="STD-Kissel-1985" TYPE="STUDY">Kissel 1985</LINK>), we searched from 1980 onwards. The bibliographies of relevant articles, reviews and textbooks cited in this review were handsearched to identify additional studies. Because no studies were found, nor any pending or unpublished studies were mentioned in the literature, it was not necessary to contact authors or experts in the field for additional studies. Readers are invited to suggest studies, particularly in other languages than English, which should be considered for inclusion when the review is updated.</P>
<SUBSECTION>
<HEADING LEVEL="3">Electronic search strategies</HEADING>
<P>The search strategy as outlined by the Cochrane Neuromuscular Disease Review Group was used. The following keywords as MeSH terms, textwords, and truncated synonyms were used to guide these searches: "non-systemic vasculitic neuropathy" OR "non-systemic vasculitis" OR "vasculitis" AND "neuropathy" OR "peripheral nervous system diseases" OR "mononeuropathies" OR "peripheral nerves" OR "muscles". The search strategies are outlined in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-07-06 15:00:18 +0100" MODIFIED_BY="Ruth Brassington">
<SUBSECTION>
<HEADING LEVEL="3">Selecting trials for inclusion</HEADING>
<P>Two authors (AV and NN) independently reviewed titles and abstracts from literature searches to identify potentially relevant trials for full review. From the full texts, trials that met the selection criteria would be selected for inclusion and graded for their methodological quality. In case of multiple publications describing the same population, either the publication with the largest number of persons or the most recent publication was used. Searches of bibliographies and texts were conducted to identify additional studies. The authors were not blinded to author and source institution. Disagreement did not occur but would have been resolved by consensus with third party adjudication (RH).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of methodological quality</HEADING>
<P>Risk of bias was to be assessed with respect to the description of the following items: allocation concealment of treatment, randomisation, confounding, patient blinding, observer blinding, explicit diagnostic inclusion and exclusion criteria, completeness of follow-up. Each item was to be scored according to the methods described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). The two authors (AV and NN) would have graded the risk of bias independently. In cases of disagreement, a third author (RH) was to be consulted for resolution by consensus.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methods of data extraction</HEADING>
<P>Two authors (AV and NN) would have extracted data independently onto specially designed collection forms that had been tested prior to use. Disagreements were to be resolved by consultation with a third author (RH) until consensus was reached. Missing data would have been obtained from the trial authors whenever possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Statistical analysis</HEADING>
<P>Risk ratios were to be calculated from dichotomised proportional data for each study with the Cochrane Review Manager (RevMan) software. The pooled risk ratio estimate would have been calculated to assess the overall efficacy of the studies. Heterogeneity of data would have been quantified by I<SUP>2</SUP>-analysis. If this analysis had shown heterogeneity to be low (I<SUP>2 </SUP>smaller than or equal to 25%), the Mantel-Haenszel risk ratio method was to be used. Otherwise, if heterogeneity had not been due to differences between identifiable and separable sub-groups of studies, a random-effects model with maximum likelihood estimation would have been used (<LINK REF="REF-Brockwell-2001" TYPE="REFERENCE">Brockwell 2001</LINK>; <LINK REF="REF-van-Houwelingen-2002" TYPE="REFERENCE">van Houwelingen 2002</LINK>). Standardised mean differences (SMD) were to be calculated from the mean changes in disability scores and MRC scores for each study. The pooled SMD was to be calculated for all studies. Standard deviations were to be derived for each study by calculation or extraction from the available data. If necessary, authors would have been asked for the original data. For all analyses, 95% confidence intervals would have been determined.<BR/>A sensitivity analysis would have been performed on the basis of methodological quality of the studies. Separate sensitivity analyses were to be done according to the presence or absence of individual internal validity items and for each level of allocation concealment of treatment.<BR/>In the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section, we used information from observational studies and other sources to describe side effects and costs likely to be associated with the immunosuppressive regimens considered in the review.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-07-06 15:00:20 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY_DESCRIPTION MODIFIED="2011-07-06 15:00:20 +0100" MODIFIED_BY="Ruth Brassington">
<P>For this updated review the number of studies found by the updated search strategies were: Pubmed 110 (13 new), EMBASE 203 (60 new), Cochrane Neuromuscular Disease Specialized Register 5 (0 new), Cochrane Central Register of Controlled Trials (CENTRAL) 9 studies (0 new), and Web of Science/ISI Web of Knowledge 223 (34 new).</P>
<P>In total 30 studies were identified and assessed for possible inclusion in the review, but none concerned randomised or quasi-randomised trials for the treatment of NSVN (<LINK REF="STD-Cartier-1980" TYPE="STUDY">Cartier 1980</LINK>; <LINK REF="STD-Collins-2003" TYPE="STUDY">Collins 2003</LINK>; <LINK REF="STD-Davies-1996" TYPE="STUDY">Davies 1996</LINK>; <LINK REF="STD-Dyck-1987" TYPE="STUDY">Dyck 1987</LINK>; <LINK REF="STD-Dyck-2001a" TYPE="STUDY">Dyck 2001a</LINK>; <LINK REF="STD-Dyck-2001b" TYPE="STUDY">Dyck 2001b</LINK>; <LINK REF="STD-Garc_x00e9_s-S_x00e1_nchez-2002" TYPE="STUDY">Garcés Sánchez 2002</LINK>; <LINK REF="STD-Handa-2001" TYPE="STUDY">Handa 2001</LINK>; <LINK REF="STD-Harati-1986a" TYPE="STUDY">Harati 1986a</LINK>; <LINK REF="STD-Hawke-1991" TYPE="STUDY">Hawke 1991</LINK>; <LINK REF="STD-Kararizou-2005" TYPE="STUDY">Kararizou 2005</LINK>; <LINK REF="STD-Kelkar-2002" TYPE="STUDY">Kelkar 2002</LINK>; <LINK REF="STD-Kissel-1985" TYPE="STUDY">Kissel 1985</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Lino-1998" TYPE="STUDY">Lino 1998</LINK>; <LINK REF="STD-L_x00e9_ger-1988" TYPE="STUDY">Léger 1988</LINK>; <LINK REF="STD-Mathew-2007" TYPE="STUDY">Mathew 2007</LINK>; <LINK REF="STD-Murthy-1998" TYPE="STUDY">Murthy 1998</LINK>; <LINK REF="STD-Prayson-2002" TYPE="STUDY">Prayson 2002</LINK>; <LINK REF="STD-Prayson-2003" TYPE="STUDY">Prayson 2003</LINK>; <LINK REF="STD-Restrepo-2009" TYPE="STUDY">Restrepo 2009</LINK>; <LINK REF="STD-Said-1988" TYPE="STUDY">Said 1988</LINK>; <LINK REF="STD-Seo-JH-2004" TYPE="STUDY">Seo JH 2004</LINK>; <LINK REF="STD-Singhal-1995" TYPE="STUDY">Singhal 1995</LINK>; <LINK REF="STD-Sobue-1989" TYPE="STUDY">Sobue 1989</LINK>; <LINK REF="STD-Sugiura-2006" TYPE="STUDY">Sugiura 2006</LINK>; <LINK REF="STD-Vincent-1985" TYPE="STUDY">Vincent 1985</LINK>; <LINK REF="STD-Vrancken-2004" TYPE="STUDY">Vrancken 2004</LINK>; <LINK REF="STD-Weisshaar-2002" TYPE="STUDY">Weisshaar 2002</LINK>; <LINK REF="STD-Zivkovic-2007" TYPE="STUDY">Zivkovic 2007</LINK>). Thus, all 30 studies were excluded from the review. For details of the excluded studies see the table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>There were no studies of sufficient quality that could be included.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Analyses could not be performed because no studies were included.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-07-06 15:00:22 +0100" MODIFIED_BY="Ruth Brassington">
<P>Even though the neurological symptoms in NSVN may lead to considerable disability, no adequate randomised or quasi-randomised clinical trials for its treatment have been published. In the absence of clinical trials, we have attempted to report the experience with immunosuppressive therapy in observational studies. The search identified 16 such studies that are outlined below (<LINK REF="STD-Collins-2003" TYPE="STUDY">Collins 2003</LINK>; <LINK REF="STD-Davies-1996" TYPE="STUDY">Davies 1996</LINK>; <LINK REF="STD-Dyck-1987" TYPE="STUDY">Dyck 1987</LINK>; <LINK REF="STD-Garc_x00e9_s-S_x00e1_nchez-2002" TYPE="STUDY">Garcés Sánchez 2002</LINK>; <LINK REF="STD-Handa-2001" TYPE="STUDY">Handa 2001</LINK>; <LINK REF="STD-Harati-1986a" TYPE="STUDY">Harati 1986a</LINK>; <LINK REF="STD-Hawke-1991" TYPE="STUDY">Hawke 1991</LINK>; <LINK REF="STD-Lino-1998" TYPE="STUDY">Lino 1998</LINK>; <LINK REF="STD-Kissel-1985" TYPE="STUDY">Kissel 1985</LINK>; <LINK REF="STD-Mathew-2007" TYPE="STUDY">Mathew 2007</LINK>; <LINK REF="STD-Murthy-1998" TYPE="STUDY">Murthy 1998</LINK>; <LINK REF="STD-Restrepo-2009" TYPE="STUDY">Restrepo 2009</LINK>; <LINK REF="STD-Seo-JH-2004" TYPE="STUDY">Seo JH 2004</LINK>; <LINK REF="STD-Singhal-1995" TYPE="STUDY">Singhal 1995</LINK>; <LINK REF="STD-Weisshaar-2002" TYPE="STUDY">Weisshaar 2002</LINK>; <LINK REF="STD-Vrancken-2004" TYPE="STUDY">Vrancken 2004</LINK>).</P>
<P>In five studies the investigators described consecutive individuals with vasculitic neuropathy, some of whom had NSVN. Immunosuppressive therapy consisted of prednisone alone or in combination with either azathioprine or cyclophosphamide. A favourable response was reported for most people, but treatment efficacy was not outlined separately for NSVN (<LINK REF="STD-Harati-1986a" TYPE="STUDY">Harati 1986a</LINK>; <LINK REF="STD-Hawke-1991" TYPE="STUDY">Hawke 1991</LINK>; <LINK REF="STD-Kissel-1985" TYPE="STUDY">Kissel 1985</LINK>; <LINK REF="STD-Singhal-1995" TYPE="STUDY">Singhal 1995</LINK>; <LINK REF="STD-Vrancken-2004" TYPE="STUDY">Vrancken 2004</LINK>).</P>
<P>In the other eleven observational studies of consecutive individuals with vasculitic neuropathy, the efficacy of immunosuppressive therapy in people with NSVN was more detailed. Follow-up data were available in eight of these studies, which are summarised in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>The largest study to date (<LINK REF="STD-Collins-2003" TYPE="STUDY">Collins 2003</LINK>) described treatment efficacy in a cohort of 48 consecutive participants with NSVN. The minimum follow-up was six months, with a median follow-up of 63 months. All participants received treatment with corticosteroids, 28 were initially treated with corticosteroid monotherapy (oral prednisolone, intravenous pulse methylprednisolone, or both). Intravenous pulse methylprednisolone did not result in a better outcome. Twenty participants received initial combination therapy with corticosteroids and cyclophosphamide (18 participants), azathioprine (one participant), or intravenous immunoglobulin (one participant). There was a five-year mortality of 13%, with no difference between treatment regimens. The response rate was lower with initial monotherapy (61%) than with initial combination therapy (95%). The improvement in the Prineas disability score (<LINK REF="REF-Prineas-1970" TYPE="REFERENCE">Prineas 1970</LINK>) was lower with initial monotherapy than with initial combination therapy (mean change in disability score of 0.5 versus 1.2). A lower proportion of participants with initial monotherapy had improved disability when compared to initial combination therapy (57% versus 85%). The relapse rate (59% versus 29%) and the number of participants with chronic pain (71% versus 44%) tended to be higher, and the improvement in the MRC sum score (mean change in MRC sum score of 3.5 versus 6.0) tended to be lower after initial monotherapy when compared to initial combination therapy. A total of 25 participants received combination therapy with corticosteroids and cyclophosphamide at any given time. Seven of these participants relapsed, and all participants responded to either additional treatment with corticosteroids alone (four participants) or combination therapy with corticosteroids and cyclophosphamide (three participants). Treatment related complications were more frequent in participants treated with cyclophosphamide and ultimately this immunosuppressant had to be discontinued in 19 participants (40%) because of adverse effects. Forty participants had at least two years of follow-up: chronic pain persisted in 24 participants, five were asymptomatic, 27 could walk independently, seven were ambulatory with walking aids, and one participant was non-ambulatory.</P>
<P>In another study (<LINK REF="STD-Davies-1996" TYPE="STUDY">Davies 1996</LINK>), all 25 participants with NSVN were treated with corticosteroids alone, and 13 also received either azathioprine, cyclophosphamide or methotrexate. At a median follow-up of 33 months, one participant had died (cause not stated). Fifteen participants had improved as assessed according to the Prineas disability scale, and stabilisation had occurred in eight. In one participant disability was not scored. Overall, there was a significant improvement from moderate (median disability scale score of 3) to mild disability (median disability scale score of 2). In four participants the symptoms had completely resolved, 18 participants had remained ambulant of whom three needed a walking aid, and one participant was not ambulatory.</P>
<P>In a study of 20 people with NSVN (<LINK REF="STD-Dyck-1987" TYPE="STUDY">Dyck 1987</LINK>), no new peripheral nerve deficits developed after oral prednisolone was started. However, the clinical improvement in already damaged and symptomatic nerves was not more rapid than in untreated people. At follow-up, three participants had died from unrelated causes. Sixteen of the surviving participants had remained ambulant of whom four needed a walking frame, and one participant was wheelchair bound. The overall neurological condition was considered to be worse in eight, and improved or stabilised in nine participants.</P>
<P>In three studies of people with vasculitic neuropathies, the participants with NSVN showed a favourable response to either monotherapy with corticosteroids (<LINK REF="STD-Handa-2001" TYPE="STUDY">Handa 2001</LINK>) or combination therapy with corticosteroids and either azathioprine (<LINK REF="STD-Garc_x00e9_s-S_x00e1_nchez-2002" TYPE="STUDY">Garcés Sánchez 2002</LINK>) or intravenous pulse cyclophosphamide (<LINK REF="STD-Lino-1998" TYPE="STUDY">Lino 1998</LINK>).</P>
<P>Treatment with corticosteroids alone (eight participants) or in combination with cyclophosphamide (one participant) led to improvement and good outcome of NSVN in another study (<LINK REF="STD-Murthy-1998" TYPE="STUDY">Murthy 1998</LINK>).</P>
<P>In a study of six people with NSVN (<LINK REF="STD-Restrepo-2009" TYPE="STUDY">Restrepo 2009</LINK>), all participants were treated with glucocorticoids and azathioprine, and two were treated with intravenous pulse cyclophosphamide. At six months follow-up, complete recovery was seen in five participants, and one participant had a severe course with neurological sequelae. During subsequent two years of follow up no further neurological progression was observed in any of the participants.</P>
<P>Another study of vasculitic neuropathies included six people with NSVN (<LINK REF="STD-Seo-JH-2004" TYPE="STUDY">Seo JH 2004</LINK>). Improvement was noted with prednisone monotherapy in one participant (follow-up of two years) and to a combination of prednisone and azathioprine in another participant (follow-up of six years). No improvement was noted in two participants who were treated with prednisone and cyclophosphamide (follow-up of four and 10 years). No progression occurred in one participant without treatment (follow-up of two years), and one participant was lost during follow-up. Disease duration was considerably shorter in the participants in whom treatment was efficacious (disease duration of eight and four months) as compared to the other participants (disease duration of two-and-a-half, six, and seven years).</P>
<P>A recent study (<LINK REF="STD-Mathew-2007" TYPE="STUDY">Mathew 2007</LINK>) included eleven people with NSVN (mean follow-up 37.7 months, median follow-up 35 months). One participant achieved spontaneous remission and had a good outcome without treatment. Seven participants received only treatment with prednisolone: all achieved initial remission, two relapsed, but all seven had a good outcome. Three participants received treatment with prednisolone and cyclophosphamide: remission and good outcome occurred in two, and in one no data on outcome were available.</P>
<P>One other study described eleven people with NSVN (<LINK REF="STD-Weisshaar-2002" TYPE="STUDY">Weisshaar 2002</LINK>). All participants were treated with oral prednisolone (mean follow-up 32 months, median follow-up 24 months). Five participants were treated with oral prednisolone only: in three remission and moderate to good improvement was achieved, one improved but relapsed, and in one outcome could not be assessed because follow-up was too short. Remission and moderate to good improvement was achieved with combined treatment consisting of oral prednisolone and either pulsed cyclophosphamide or methotrexate (one participant each) or azathioprine (three participants). Little improvement was seen in another participant treated with oral prednisolone and azathioprine.</P>
<P>Peripheral neuropathy belongs to the initial manifestations of systemic vasculitis, because the axons in peripheral nerves are susceptible to ischaemia (<LINK REF="REF-Fujimura-1991" TYPE="REFERENCE">Fujimura 1991</LINK>; <LINK REF="REF-Nukada-1987" TYPE="REFERENCE">Nukada 1987</LINK>; <LINK REF="REF-Nukada-1996" TYPE="REFERENCE">Nukada 1996</LINK>) and damage occurs early in the course of vasculitis (<LINK REF="REF-Exley-1997" TYPE="REFERENCE">Exley 1997</LINK>; <LINK REF="REF-Seo-P-2005" TYPE="REFERENCE">Seo P 2005</LINK>). Early diagnosis and initiation of immunosuppressive treatment that limits or reverses the detrimental effects and prevents disease progression or relapses could be expected to improve vasculitic neuropathy, disability and prognosis as observed in uncontrolled follow-up studies in systemic vasculitis (<LINK REF="REF-Cattaneo-2007" TYPE="REFERENCE">Cattaneo 2007</LINK>; <LINK REF="REF-Chang-1984" TYPE="REFERENCE">Chang 1984</LINK>; <LINK REF="REF-Danieli-2004" TYPE="REFERENCE">Danieli 2004</LINK>; <LINK REF="REF-de-Groot-2001" TYPE="REFERENCE">de Groot 2001</LINK>; <LINK REF="REF-Hattori-1999" TYPE="REFERENCE">Hattori 1999</LINK>; <LINK REF="REF-Hattori-2002" TYPE="REFERENCE">Hattori 2002</LINK>; <LINK REF="STD-Hawke-1991" TYPE="STUDY">Hawke 1991</LINK>; <LINK REF="STD-Mathew-2007" TYPE="STUDY">Mathew 2007</LINK>; <LINK REF="REF-Moore-1981" TYPE="REFERENCE">Moore 1981</LINK>; <LINK REF="STD-Seo-JH-2004" TYPE="STUDY">Seo JH 2004</LINK>).</P>
<P>To date there has been one confirmed autopsy case of truly isolated vasculitic neuropathy (<LINK REF="REF-Kernohan-1938" TYPE="REFERENCE">Kernohan 1938</LINK>), and for several other reasons it has been debated that NSVN is truly non-systemic. People who present with apparently isolated vasculitic neuropathy or NSVN can progress to develop systemic disease even after a considerable latency (<LINK REF="REF-Agard-2003" TYPE="REFERENCE">Agard 2003</LINK>; <LINK REF="REF-Cattaneo-2007" TYPE="REFERENCE">Cattaneo 2007</LINK>; <LINK REF="STD-Collins-2003" TYPE="STUDY">Collins 2003</LINK>; <LINK REF="REF-de-Groot-2001" TYPE="REFERENCE">de Groot 2001</LINK>; <LINK REF="REF-Greenberg-2002" TYPE="REFERENCE">Greenberg 2002</LINK>; <LINK REF="REF-Hattori-1999" TYPE="REFERENCE">Hattori 1999</LINK>; <LINK REF="REF-Hattori-2002" TYPE="REFERENCE">Hattori 2002</LINK>; <LINK REF="REF-Moore-1981" TYPE="REFERENCE">Moore 1981</LINK>; <LINK REF="REF-Mori-2005" TYPE="REFERENCE">Mori 2005</LINK>; <LINK REF="REF-Said-2005" TYPE="REFERENCE">Said 2005</LINK>; <LINK REF="REF-S_x00e1_nchez-2001" TYPE="REFERENCE">Sánchez 2001</LINK>). The frequency of this progression remains uncertain and depends on the extensiveness of ancillary investigations performed to exclude any underlying diseases. In addition, there are no prospective studies that investigated if people with isolated vasculitic neuropathy or NSVN fulfilled classification criteria for systemic vasculitis or rheumatic disease from the onset of the neuropathy. The involvement of muscle tissue could be considered to suggest that the vasculitis in NSVN is more extensive than suspected or detected on clinical grounds (<LINK REF="STD-Prayson-2002" TYPE="STUDY">Prayson 2002</LINK>; <LINK REF="STD-Prayson-2003" TYPE="STUDY">Prayson 2003</LINK>; <LINK REF="REF-Pu_x00e9_chal-1999" TYPE="REFERENCE">Puéchal 1999</LINK>; <LINK REF="STD-Said-1988" TYPE="STUDY">Said 1988</LINK>; <LINK REF="REF-Said-2005" TYPE="REFERENCE">Said 2005</LINK>; <LINK REF="REF-Younger-2004" TYPE="REFERENCE">Younger 2004</LINK>). Besides, the vasculitic lesions in nerve or muscle tissue are indistinguishable from those in systemic vasculitis such as polyarteritis nodosa, microscopic polyangiitis or cutaneous leukocytoclastic angiitis (<LINK REF="STD-Handa-2001" TYPE="STUDY">Handa 2001</LINK>; <LINK REF="REF-Jennette-1997" TYPE="REFERENCE">Jennette 1997</LINK>; <LINK REF="STD-Sugiura-2006" TYPE="STUDY">Sugiura 2006</LINK>; <LINK REF="REF-Vital-2006" TYPE="REFERENCE">Vital 2006</LINK>; <LINK REF="STD-Vrancken-2004" TYPE="STUDY">Vrancken 2004</LINK>). There are cases with only peripheral nerve and muscle manifestations in whom magnetic resonance angiography or conventional angiography demonstrated the involvement of more proximal and larger elastic type arteries of the legs, or multiple micro-aneurysms or stenoses in gastrointestinal or renal arteries (<LINK REF="REF-Sanada-2003" TYPE="REFERENCE">Sanada 2003</LINK>; <LINK REF="REF-Selga-2006" TYPE="REFERENCE">Selga 2006</LINK>), which would preclude a diagnosis of NSVN. Nevertheless, localised forms of vasculitis including muscular polyarteritis nodosa have been recognised (<LINK REF="REF-Ali-2007" TYPE="REFERENCE">Ali 2007</LINK>; <LINK REF="REF-Balbir_x002d_Gurman-2007" TYPE="REFERENCE">Balbir-Gurman 2007</LINK>; <LINK REF="REF-Carlson-2007" TYPE="REFERENCE">Carlson 2007</LINK>; <LINK REF="REF-Gallien-2002" TYPE="REFERENCE">Gallien 2002</LINK>; <LINK REF="REF-Hernandez_x002d_Rodriguez-2008" TYPE="REFERENCE">Hernandez-Rodriguez 2008</LINK>; <LINK REF="REF-Kamimura-2005" TYPE="REFERENCE">Kamimura 2005</LINK>; <LINK REF="REF-Khellaf-2007" TYPE="REFERENCE">Khellaf 2007</LINK>; <LINK REF="REF-Nakamura-2003" TYPE="REFERENCE">Nakamura 2003</LINK>; <LINK REF="REF-Quinet-2003" TYPE="REFERENCE">Quinet 2003</LINK>), cutaneous leukocytoclastic vasculitis is a separate entity within vasculitis classification systems (<LINK REF="REF-Jennette-1997" TYPE="REFERENCE">Jennette 1997</LINK>; <LINK REF="REF-Kallenberg-2008" TYPE="REFERENCE">Kallenberg 2008</LINK>; <LINK REF="REF-Lie-1997" TYPE="REFERENCE">Lie 1997</LINK>; <LINK REF="REF-Nakamura-2009" TYPE="REFERENCE">Nakamura 2009</LINK>), and isolated vasculitic neuropathy or NSVN has received increased attention in the rheumatologic literature (<LINK REF="REF-Abgrall-2001" TYPE="REFERENCE">Abgrall 2001</LINK>; <LINK REF="REF-Collins-2005" TYPE="REFERENCE">Collins 2005</LINK>; <LINK REF="REF-Collins-2008" TYPE="REFERENCE">Collins 2008</LINK>; <LINK REF="REF-De-la-Sayette-1995" TYPE="REFERENCE">De la Sayette 1995</LINK>; <LINK REF="STD-Kararizou-2005" TYPE="STUDY">Kararizou 2005</LINK>; <LINK REF="REF-Pu_x00e9_chal-1999" TYPE="REFERENCE">Puéchal 1999</LINK>; <LINK REF="STD-Restrepo-2009" TYPE="STUDY">Restrepo 2009</LINK>).</P>
<P>Regardless of the premise that NSVN is a separate disease entity, an alternative therapeutic approach would be to test immunosuppressive agents that are efficacious in systemic vasculitis or vasculitis in connective tissue diseases. Randomised trials have been performed in these disorders, but the quality was variable as allocation concealment of treatment was often not done or unclear, treatment was generally unblinded, and intention-to-treat analysis was not always performed (<LINK REF="REF-Collins-2010" TYPE="REFERENCE">Collins 2010</LINK>).</P>
<P>Corticosteroids, mostly given in the form of oral prednisolone, became the cornerstone of treatment in primary vasculitis after it was demonstrated in observational studies that the use improved survival and reduced disease related complications (<LINK REF="REF-Cohen-1980" TYPE="REFERENCE">Cohen 1980</LINK>; <LINK REF="REF-Fauci-1978" TYPE="REFERENCE">Fauci 1978</LINK>; <LINK REF="REF-Fauci-1983" TYPE="REFERENCE">Fauci 1983</LINK>; <LINK REF="REF-Frohnert-1967" TYPE="REFERENCE">Frohnert 1967</LINK>; <LINK REF="REF-Guillevin-1985" TYPE="REFERENCE">Guillevin 1985</LINK>; <LINK REF="REF-Leib-1979" TYPE="REFERENCE">Leib 1979</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>; <LINK REF="REF-Pipitone-2008" TYPE="REFERENCE">Pipitone 2008</LINK>). Open randomised trials showed that in the absence of poor prognostic factors, people with systemic vasculitis and limited disease may be treated effectively with prednisolone alone (<LINK REF="REF-Bosch-2007" TYPE="REFERENCE">Bosch 2007</LINK>; <LINK REF="REF-Mouthon-2002" TYPE="REFERENCE">Mouthon 2002</LINK>; <LINK REF="REF-Mukhtyar-2008" TYPE="REFERENCE">Mukhtyar 2008</LINK>; <LINK REF="REF-Ribi-2008" TYPE="REFERENCE">Ribi 2008</LINK>). In giant cell arteritis fewer flare-ups occurred with a daily regimen than with alternate-day oral prednisolone, but the value of intravenous pulses methylprednisolone remains uncertain (<LINK REF="REF-Mukhtyar-2009a" TYPE="REFERENCE">Mukhtyar 2009a</LINK>; <LINK REF="REF-Pipitone-2008" TYPE="REFERENCE">Pipitone 2008</LINK>). Given the evidence from trials in systemic vasculitis, initial treatment with oral prednisolone may in the opinion of the authors be justified in patients with NSVN, particularly in those who are severely affected (<LINK REF="REF-Collins-2010" TYPE="REFERENCE">Collins 2010</LINK>).</P>
<P>The addition of oral cyclophosphamide to corticosteroids for the treatment of systemic vasculitis further reduced mortality and could induce long-term remission in observational studies, though at the expense of cyclophosphamide related complications (<LINK REF="REF-Cohen-1980" TYPE="REFERENCE">Cohen 1980</LINK>; <LINK REF="REF-Fauci-1979" TYPE="REFERENCE">Fauci 1979</LINK>; <LINK REF="REF-Fauci-1983" TYPE="REFERENCE">Fauci 1983</LINK>; <LINK REF="REF-Leib-1979" TYPE="REFERENCE">Leib 1979</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>; <LINK REF="REF-Nachman-1996" TYPE="REFERENCE">Nachman 1996</LINK>; <LINK REF="REF-Scott-1984" TYPE="REFERENCE">Scott 1984</LINK>). Especially in patients with moderate to severe and persistent disease activity or poor prognostic factors, the superiority of combination therapy of corticosteroids with oral cyclophosphamide was demonstrated in open randomised trials (<LINK REF="REF-Bosch-2007" TYPE="REFERENCE">Bosch 2007</LINK>; <LINK REF="REF-Jayne-2008" TYPE="REFERENCE">Jayne 2008</LINK>; <LINK REF="REF-Mouthon-2002" TYPE="REFERENCE">Mouthon 2002</LINK>; <LINK REF="REF-Mukhtyar-2008" TYPE="REFERENCE">Mukhtyar 2008</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>). Because of the cumulative toxicity of oral cyclophosphamide (<LINK REF="REF-Marder-2004" TYPE="REFERENCE">Marder 2004</LINK>), several randomised trials evaluated the efficacy of intravenous pulsed cyclophosphamide. With intravenous pulsed cyclophosphamide the cumulative dose was lower, toxic side-effects were less frequent, but induction of remission was less successful and relapse rates were higher unless an increased number of pulses was used (<LINK REF="REF-Bosch-2007" TYPE="REFERENCE">Bosch 2007</LINK>; <LINK REF="REF-de-Groot-2009" TYPE="REFERENCE">de Groot 2009</LINK>; <LINK REF="REF-Jayne-2008" TYPE="REFERENCE">Jayne 2008</LINK>; <LINK REF="REF-Langford-2005" TYPE="REFERENCE">Langford 2005</LINK>; <LINK REF="REF-Mukhtyar-2008" TYPE="REFERENCE">Mukhtyar 2008</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>; <LINK REF="REF-Walters-2008" TYPE="REFERENCE">Walters 2008</LINK>). In NSVN, induction of remission with a combination of corticosteroids and cyclophosphamide needs further investigation, as well as the question of whether oral or intravenous pulsed cyclophosphamide regimens are better (<LINK REF="REF-Collins-2010" TYPE="REFERENCE">Collins 2010</LINK>).</P>
<P>Because of their potential steroid sparing effect and relatively more favourable toxicity profiles in comparison to cyclophosphamide (<LINK REF="REF-Marder-2004" TYPE="REFERENCE">Marder 2004</LINK>), various other immunosuppressive agents have been investigated in mostly unblinded randomised trials.</P>
<P>Methotrexate has been investigated in randomised trials as adjuvant treatment to oral prednisolone in polymyalgia rheumatica and giant cell arteritis, but the beneficial effect is modest and it is only recommended in refractory disease or cases at risk for adverse effects of corticosteroids (<LINK REF="REF-Caporali-2004" TYPE="REFERENCE">Caporali 2004</LINK>; <LINK REF="REF-Cimmino-2008" TYPE="REFERENCE">Cimmino 2008</LINK>; <LINK REF="REF-Mukhtyar-2009a" TYPE="REFERENCE">Mukhtyar 2009a</LINK>; <LINK REF="REF-Pipitone-2008" TYPE="REFERENCE">Pipitone 2008</LINK>; <LINK REF="REF-van-der-Veen-1996" TYPE="REFERENCE">van der Veen 1996</LINK>). In a randomised trial for rheumatoid vasculitis, combined therapy with prednisolone and methotrexate was inferior to prednisolone and cyclophosphamide (<LINK REF="REF-Rell_x002d_Bakalarska-1998" TYPE="REFERENCE">Rell-Bakalarska 1998</LINK>). In systemic vasculitis combined treatment with prednisolone and methotrexate could replace prednisolone and oral cyclophosphamide for induction of remission especially in early non-extensive disease, although there was an increased relapse rate; methotrexate, etanercept or azathioprine showed comparable efficacy for the maintenance of remission after induction of remission with prednisolone and oral cyclophosphamide (<LINK REF="REF-Bosch-2007" TYPE="REFERENCE">Bosch 2007</LINK>; <LINK REF="REF-Jayne-2008" TYPE="REFERENCE">Jayne 2008</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>; <LINK REF="REF-Mukhtyar-2008" TYPE="REFERENCE">Mukhtyar 2008</LINK>; <LINK REF="REF-Pagnoux-2008" TYPE="REFERENCE">Pagnoux 2008</LINK>; <LINK REF="REF-WGET-Research-Group-2005" TYPE="REFERENCE">WGET Research Group 2005</LINK>). In a randomised trial for Wegener's granulomatosis, methotrexate was less efficacious than leflunomide in maintaining remission (<LINK REF="REF-Metzler-2007" TYPE="REFERENCE">Metzler 2007</LINK>), but the use of leflunomide could be limited since leflunomide-induced neuropathy has been reported (<LINK REF="REF-Martin-2007" TYPE="REFERENCE">Martin 2007</LINK>; <LINK REF="REF-Richards-2007" TYPE="REFERENCE">Richards 2007</LINK>). Prednisolone in combination with methotrexate has been recommended as a less toxic alternative to the combination with cyclophosphamide in limited non-organ or non-life threatening vasculitis (<LINK REF="REF-Bosch-2007" TYPE="REFERENCE">Bosch 2007</LINK>; <LINK REF="REF-Mukhtyar-2008" TYPE="REFERENCE">Mukhtyar 2008</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>). Methotrexate could therefore be a promising and preferable addition to prednisolone for the treatment of NSVN (<LINK REF="REF-Collins-2010" TYPE="REFERENCE">Collins 2010</LINK>).</P>
<P>A few small randomised trials in rheumatoid vasculitis, and giant cell arteritis or polymyalgia rheumatica showed at most only a small benefit of azathioprine as adjuvant treatment to prednisolone (<LINK REF="REF-De-Silva-1986" TYPE="REFERENCE">De Silva 1986</LINK>; <LINK REF="REF-Heurkens-1991" TYPE="REFERENCE">Heurkens 1991</LINK>; <LINK REF="REF-Nicholls-1973" TYPE="REFERENCE">Nicholls 1973</LINK>). For this reason azathioprine has not become favoured as additional treatment to prednisolone in these diseases (<LINK REF="REF-Mukhtyar-2009a" TYPE="REFERENCE">Mukhtyar 2009a</LINK>; <LINK REF="REF-Pipitone-2008" TYPE="REFERENCE">Pipitone 2008</LINK>). In systemic vasculitis, randomised trials showed that sequential therapy for maintenance of remission with prednisolone and azathioprine was not inferior in efficacy and less toxic when compared to prednisolone and cyclophosphamide (<LINK REF="REF-Bosch-2007" TYPE="REFERENCE">Bosch 2007</LINK>; <LINK REF="REF-Jayne-2003" TYPE="REFERENCE">Jayne 2003</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>; <LINK REF="REF-Ribi-2008" TYPE="REFERENCE">Ribi 2008</LINK>). Mycophenolate mofetil was similarly beneficial in non-randomised studies (<LINK REF="REF-Bosch-2007" TYPE="REFERENCE">Bosch 2007</LINK>; <LINK REF="REF-Hu-2008" TYPE="REFERENCE">Hu 2008</LINK>; <LINK REF="REF-Jayne-2008" TYPE="REFERENCE">Jayne 2008</LINK>; <LINK REF="REF-Kazderova-2008" TYPE="REFERENCE">Kazderova 2008</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>). The long-term efficacy of both agents requires confirmation in randomised trials (<LINK REF="REF-Iaccarino-2007" TYPE="REFERENCE">Iaccarino 2007</LINK>; <LINK REF="REF-Langford-2005" TYPE="REFERENCE">Langford 2005</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>), but azathioprine as adjuvant treatment to prednisolone for NSVN would be worth investigating (<LINK REF="REF-Collins-2010" TYPE="REFERENCE">Collins 2010</LINK>).</P>
<P>Experience with TNF&#945; inhibitors (e.g. etanercept, infliximab) or other biological immunomodulatory agents (e.g. rituximab, alemtuzumab, IFN&#945;, cyclosporin A) in systemic vasculitis and autoimmune or connective tissue disease is too fragmented to draw definite conclusions about efficacy (<LINK REF="REF-Bosch-2007" TYPE="REFERENCE">Bosch 2007</LINK>; <LINK REF="REF-Cavallo-2009" TYPE="REFERENCE">Cavallo 2009</LINK>; <LINK REF="REF-Chung-2009" TYPE="REFERENCE">Chung 2009</LINK>; <LINK REF="REF-Jayne-2008" TYPE="REFERENCE">Jayne 2008</LINK>; <LINK REF="REF-Lovric-2009" TYPE="REFERENCE">Lovric 2009</LINK>; <LINK REF="REF-Martinez_x002d_Taboada-2008" TYPE="REFERENCE">Martinez-Taboada 2008</LINK>; <LINK REF="REF-Mukhtyar-2009a" TYPE="REFERENCE">Mukhtyar 2009a</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>; <LINK REF="REF-Mukhtyar-2008" TYPE="REFERENCE">Mukhtyar 2008</LINK>; <LINK REF="REF-Salvarani-2008" TYPE="REFERENCE">Salvarani 2008</LINK>; <LINK REF="REF-Schaufelberger-2006" TYPE="REFERENCE">Schaufelberger 2006</LINK>; <LINK REF="REF-St_x00fc_bgen-2008b" TYPE="REFERENCE">Stübgen 2008b</LINK>). There is insufficient evidence for their use in NSVN. Besides, some TNF&#945; inhibitors have been associated with autoimmune inflammatory neuropathies including vasculitic neuropathy (<LINK REF="REF-St_x00fc_bgen-2008a" TYPE="REFERENCE">Stübgen 2008a</LINK>), which could limit their use.</P>
<P>Treatment with intravenous immunoglobulins (IVIg) has been proven to be efficacious in several immune-mediated neuromuscular disorders and is considered first choice in chronic inflammatory demyelinating polyradiculoneuropathy, Guillain-Barré syndrome and multifocal motor neuropathy (<LINK REF="REF-Hughes-2008" TYPE="REFERENCE">Hughes 2008</LINK>). IVIg has been used as adjuvant treatment in systemic vasculitis and connective tissue disease with concomitant neuropathy, but the experience from the small open studies remains to be confirmed in randomised trials (<LINK REF="REF-Bosch-2007" TYPE="REFERENCE">Bosch 2007</LINK>; <LINK REF="REF-Braun_x002d_Moscovici-2003b" TYPE="REFERENCE">Braun-Moscovici 2003b</LINK>; <LINK REF="REF-Danieli-2004" TYPE="REFERENCE">Danieli 2004</LINK>; <LINK REF="REF-Levy-1999" TYPE="REFERENCE">Levy 1999</LINK>; <LINK REF="REF-Levy-2005" TYPE="REFERENCE">Levy 2005</LINK>; <LINK REF="REF-Martinez-2008" TYPE="REFERENCE">Martinez 2008</LINK>; <LINK REF="REF-Mori-2005" TYPE="REFERENCE">Mori 2005</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>; <LINK REF="REF-Steinbrecher-2006" TYPE="REFERENCE">Steinbrecher 2006</LINK>; <LINK REF="REF-Taniguchi-2007" TYPE="REFERENCE">Taniguchi 2007</LINK>; <LINK REF="REF-Tsurikisawa-2004" TYPE="REFERENCE">Tsurikisawa 2004</LINK>). More evidence is needed before considering IVIg as an adjuvant treatment option for NSVN.</P>
<P>Except for cases presenting with acute severe disease or acute renal failure and for treatment of virus-induced or cryoglobulinaemic vasculitis, the addition of plasma exchange to standard therapy with prednisolone and cyclophosphamide or other immunosuppressants has no proven benefit in systemic vasculitis and autoimmune or connective tissue disease (<LINK REF="REF-Bosch-2007" TYPE="REFERENCE">Bosch 2007</LINK>; <LINK REF="REF-Braun_x002d_Moscovici-2003a" TYPE="REFERENCE">Braun-Moscovici 2003a</LINK>; <LINK REF="REF-Guillevin-2007" TYPE="REFERENCE">Guillevin 2007</LINK>; <LINK REF="REF-Jayne-2008" TYPE="REFERENCE">Jayne 2008</LINK>; <LINK REF="REF-Mukhtyar-2009b" TYPE="REFERENCE">Mukhtyar 2009b</LINK>; <LINK REF="REF-Mukhtyar-2008" TYPE="REFERENCE">Mukhtyar 2008</LINK>; <LINK REF="REF-Shehata-2002" TYPE="REFERENCE">Shehata 2002</LINK>; <LINK REF="REF-Walters-2008" TYPE="REFERENCE">Walters 2008</LINK>). There is no indication for plasma exchange as treatment of NSVN.</P>
<P>Although the results from observational studies and mostly unblinded randomised trials in systemic vasculitis suggest that corticosteroids alone or in combination with immunosuppressive agents such as cyclophosphamide, methotrexate, azathioprine, and possibly mycophenolate mofetil or IVIg may be effective, it remains uncertain if that evidence can simply be extrapolated to guide treatment of NSVN. The lack of multi-organ involvement in NSVN may argue against the use of aggressive and potentially toxic combination therapy. Until evidence from randomised trials becomes available, corticosteroids are generally considered the treatment of choice for NSVN (<LINK REF="REF-Collins-2010" TYPE="REFERENCE">Collins 2010</LINK>). Because NSVN is a potentially disabling disease and given that in mild or limited forms of systemic vasculitis initial treatment consists of corticosteroids, in the view of the authors of this review, a placebo-controlled randomised trial of corticosteroids in NSVN would not be justifiable and is unlikely to be performed. However, randomised controlled trials would be appropriate to determine the value of corticosteroids alone compared to other immunosuppressive adjuvant or combination regimens.</P>
<P>Because NSVN is rare and progression to systemic involvement should be excluded, multicentre clinical trials with long-term follow-up will be required to determine which treatments are efficacious. Alternatively, as it may be difficult to carry out a trial due to the rarity of NSVN, evidence on possible efficacious treatment options could be obtained from data about peripheral neuropathy in previous or ongoing randomised trials in systemic vasculitis. The rapid progression and considerable disability would not make it too difficult to choose adequate outcome measures. Randomised trials should be designed to assess the effects of treatment on outcomes of interest to people with the disease. We would recommend the selection of a sensitive disability outcome measure as being more directly relevant to patients' needs than an electrophysiological, pathological or impairment measure. Even though we preferred the modified Rankin scale for this review, a more gradual scale designed for measuring disability in peripheral neuropathy might be superior. Disability scores designed to measure upper and lower limb disability or a walking scale which have been validated for assessing change and which reflect the patients' judgment in immune-mediated inflammatory neuropathies should be considered (<LINK REF="REF-Graham-2006a" TYPE="REFERENCE">Graham 2006a</LINK>; <LINK REF="REF-Graham-2006b" TYPE="REFERENCE">Graham 2006b</LINK>; <LINK REF="REF-Merkies-2006" TYPE="REFERENCE">Merkies 2006</LINK>).</P>
<P>Evidence-based data on which to base treatment decisions for NSVN are of paramount importance, but along with the wide clinical variability of the disease, requirements for sophisticated biopsy techniques and pathological interpretation, difficulty with blinding when drugs like prednisolone, cyclophosphamide or other immunosuppressants are involved, as well as ethical issues, the feasibility of randomised controlled trials is limited. Moreover, since NSVN is by definition a limited form of vasculitis, it will be particularly important to identify treatments which are not hampered by serious adverse effects. The difficulty of performing randomised controlled trials in such a rare disease is a challenge to the international neurological community to organise the multicentre trials needed to answer the unresolved questions.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-11-10 17:23:50 +0000" MODIFIED_BY="Ruth Brassington">
<IMPLICATIONS_PRACTICE MODIFIED="2009-09-02 14:45:19 +0100" MODIFIED_BY="Ruth Brassington">
<P>There are no randomised trials on which to base immunosuppressive treatment for NSVN. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-11-10 17:23:50 +0000" MODIFIED_BY="Ruth Brassington">
<P>Blinded randomised trials comparing the efficacy of corticosteroids alone to combination therapy with corticosteroids and cyclophosphamide or preferably other less toxic immunosuppressants such as methotrexate, azathioprine, or perhaps IVIg or mycophenolate mofetil are needed for NSVN. Randomised trials need to be adequately powered, and therefore multicentre, and long term. Their primary outcomes should be disability measured with scales designed and validated for assessing change in peripheral neuropathy of this type.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>None.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-08-10 15:21:42 +0100" MODIFIED_BY="Ruth Brassington">
<P>Richard Hughes holds consultancies with the following companies which produce intravenous immunoglobulin or immunosuppressive drugs: Baxter, LFB, Novartis, Octapharma and Talecris. </P>
<P>Alexander Vrancken, John Wokke, Nicolette Notermans, Gérard Said: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Alexander Vrancken, Richard Hughes and Nicolette Notermans contributed substantially to the concept and design of the review. Alexander Vrancken wrote the first draft of the review, and with the other co-reviewers contributed to subsequent revisions for important intellectual content. All reviewers agreed to the final version of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-11-10 17:23:15 +0000" MODIFIED_BY="Ruth Brassington">
<P>In the update of this review the intentions have been declared to include 'Risk of bias' and 'Summary of findings' tables when randomised trials become available.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2013-03-04 15:17:42 +0000" MODIFIED_BY="Ruth Brassington">
<P>New evidence on this topic is slow to emerge. The next update of the review is planned for 2015, which is four years after the last search rather than the usual two years. If trials are published in the interim an earlier update will be scheduled.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-06-29 11:30:58 +0100" MODIFIED_BY="Ruth Brassington">
<STUDIES MODIFIED="2011-02-07 15:14:42 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2011-02-07 15:14:42 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Cartier-1980" MODIFIED="2009-05-17 00:37:34 +0100" MODIFIED_BY="[Empty name]" NAME="Cartier 1980" YEAR="1980">
<REFERENCE MODIFIED="2009-05-17 00:37:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cartier L, Quintana J, Vergara F</AU>
<TI>Mononeuritis multiplex associated with necrotizing vasculitis</TI>
<TO>Mononeuritis multiple por angiopatia necrotizante</TO>
<SO>Revista Medica de Chile</SO>
<YR>1980</YR>
<VL>108</VL>
<NO>6</NO>
<PG>519-26</PG>
<IDENTIFIERS MODIFIED="2009-05-13 21:56:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="6110230"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-2003" NAME="Collins 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins MP, Periquet MI, Mendell JR, Sahenk Z, Nagaraja HN, Kissel JT</AU>
<TI>Nonsystemic vasculitic neuropathy: insights from a clinical cohort</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>61</VL>
<NO>5</NO>
<PG>623-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-1996" NAME="Davies 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies L, Spies JM, Pollard JD, McLeod JG</AU>
<TI>Vasculitis confined to peripheral nerves</TI>
<SO>Brain</SO>
<YR>1996</YR>
<VL>119</VL>
<NO>Pt 5</NO>
<PG>1441-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dyck-1987" NAME="Dyck 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dyck PJ, Benstead TJ, Conn DL, Stevens JC, Windebank AJ, Low PA</AU>
<TI>Nonsystemic vasculitic neuropathy</TI>
<SO>Brain</SO>
<YR>1987</YR>
<VL>110</VL>
<NO>Pt 4</NO>
<PG>843-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dyck-2001a" NAME="Dyck 2001a" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dyck PJ, Norell JE, Dyck PJ</AU>
<TI>Non-diabetic lumbosacral radiculoplexus neuropathy: natural history, outcome and comparison with the diabetic variety</TI>
<SO>Brain</SO>
<YR>2001</YR>
<VL>124</VL>
<NO>Pt 6</NO>
<PG>1197-207</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dyck-2001b" NAME="Dyck 2001b" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dyck PJ, Norell JE, Dyck PJ</AU>
<TI>Methylprednisolone may improve lumbosacral radiculoplexus neuropathy</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>3</NO>
<PG>224-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garc_x00e9_s-S_x00e1_nchez-2002" NAME="Garcés Sánchez 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcés Sánchez M, Villanueva-Haba VE, Sevilla Mantecón T, Mayordomo Fernández F, Vílchez Padilla JJ</AU>
<TI>Nonsystemic vasculitic neuropathy</TI>
<TO>Neuropatía vasculítica no sistémica</TO>
<SO>Neurología (Barcelona)</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>10</NO>
<PG>616-20</PG>
<CY>Barcelona</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Handa-2001" NAME="Handa 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Handa R, Wali JP, Gupta SD, Dinda AK, Aggarwal P, Wig N, et al</AU>
<TI>Classical polyarteritis nodosa and microscopic polyangiitis--a clinicopathologic study</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>2001</YR>
<VL>49</VL>
<PG>314-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harati-1986a" MODIFIED="2009-09-02 14:50:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="Harati 1986a" YEAR="1986">
<REFERENCE MODIFIED="2009-09-02 14:50:07 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harati Y, Niakan E</AU>
<TI>The clinical spectrum of inflammatory-angiopathic neuropathy</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1986</YR>
<VL>49</VL>
<NO>11</NO>
<PG>1313-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hawke-1991" NAME="Hawke 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawke SH, Davies L, Pamphlett R, Guo YP, Pollard JD, McLeod JG</AU>
<TI>Vasculitic neuropathy. A clinical and pathological study</TI>
<SO>Brain</SO>
<YR>1991</YR>
<VL>114</VL>
<NO>Pt 5</NO>
<PG>2175-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kararizou-2005" NAME="Kararizou 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kararizou E, Davaki P, Karandreas N, Davou R, Vassilopoulos D</AU>
<TI>Nonsystemic vasculitic neuropathy: a clinicopathological study of 22 cases</TI>
<SO>Journal of Rheumatology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>5</NO>
<PG>853-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelkar-2002" NAME="Kelkar 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelkar P, McDermott WR, Parry GJ</AU>
<TI>Sensory-predominant, painful, idiopathic neuropathy: inflammatory changes in sural nerves</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>3</NO>
<PG>413-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kissel-1985" NAME="Kissel 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kissel JT, Slivka AP, Warmolts JR, Mendell JR</AU>
<TI>The clinical spectrum of necrotizing angiopathy of the peripheral nervous system</TI>
<SO>Annals of Neurology</SO>
<YR>1985</YR>
<VL>18</VL>
<NO>2</NO>
<PG>251-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2005" NAME="Lee 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee JE, Shun CT, Hsieh SC, Hsieh ST</AU>
<TI>Skin denervation in vasculitic neuropathy</TI>
<SO>Archives of Neurology</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>10</NO>
<PG>1570-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x00e9_ger-1988" MODIFIED="2009-11-10 17:03:04 +0000" MODIFIED_BY="Ruth Brassington" NAME="Léger 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-11-10 17:03:04 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Léger J-M, Bouche P, Chaunu MP, Hauw JJ, Brunet P, Cathala HP, et al</AU>
<TI>Peripheral neuropathy with neural vasculitis. Clinical and electrophysiological features of 33 cases</TI>
<TO>Neuropathies périphériques avec vasculite nerveuse. Aspects cliniques et électrophysiologiques de 33 cas</TO>
<SO>La Presse Médicale</SO>
<YR>1988</YR>
<VL>17</VL>
<NO>15</NO>
<PG>733-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lino-1998" NAME="Lino 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lino AMM, Hirata MTA, Beata AM, Tsanaclis AMC, Scaff M, Marchiori PE</AU>
<TI>Intravenous therapy with methylprednisolone and cyclophosphamide in vasculitis of peripheral nervous system: evaluation of eight patients</TI>
<SO>Arquivos de Neuro-Psiquiatria</SO>
<YR>1998</YR>
<VL>56</VL>
<NO>2</NO>
<PG>274-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathew-2007" MODIFIED="2009-05-17 00:39:15 +0100" MODIFIED_BY="[Empty name]" NAME="Mathew 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-05-17 00:39:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathew L, Talbot K, Love S, Puvanarajah S, Donaghy M</AU>
<TI>Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>2007</YR>
<VL>100</VL>
<NO>1</NO>
<PG>41-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17189246"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murthy-1998" NAME="Murthy 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murthy JM, Sundaram C, Meena AK</AU>
<TI>Nonsystemic vasculitic neuropathy</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1998</YR>
<VL>46</VL>
<NO>2</NO>
<PG>204-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prayson-2002" MODIFIED="2009-07-19 16:49:42 +0100" MODIFIED_BY="[Empty name]" NAME="Prayson 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-19 16:49:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prayson RA</AU>
<TI>Skeletal muscle vasculitis exclusive of inflammatory myopathic conditions: a clinicopathologic study of 40 patients</TI>
<SO>Human Pathology</SO>
<YR>2002</YR>
<VL>33</VL>
<NO>10</NO>
<PG>989-95</PG>
<IDENTIFIERS MODIFIED="2009-05-17 20:36:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12395371"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prayson-2003" NAME="Prayson 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prayson RA, Sedlock DJ</AU>
<TI>Clinicopathologic study of 43 patients with sural nerve vasculitis</TI>
<SO>Human Pathology</SO>
<YR>2003</YR>
<VL>34</VL>
<NO>5</NO>
<PG>484-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Restrepo-2009" MODIFIED="2011-02-07 15:14:42 +0000" MODIFIED_BY="[Empty name]" NAME="Restrepo 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-02-07 15:14:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Restrepo JF, Rondon F, Matteson EL, Colegial CH, Quintana G, Iglesias-Gamarra A</AU>
<TI>Necrotizing lymphocytic vasculitis limited to the peripheral nerves: report of six cases and review</TI>
<SO>International Journal of Rheumatology</SO>
<YR>2009</YR>
<VL>2009</VL>
<PG>Article ID 368032, 5 pages</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20204175"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Said-1988" NAME="Said 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Said G, Lacroix-Ciaudo C, Fujimura H, Blas C, Faux N</AU>
<TI>The peripheral neuropathy of necrotizing arteritis: a clinicopathological study</TI>
<SO>Annals of Neurology</SO>
<YR>1988</YR>
<VL>23</VL>
<NO>5</NO>
<PG>461-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seo-JH-2004" NAME="Seo JH 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seo JH, Ryan HF, Claussen GC, Thomas TD, Oh SJ</AU>
<TI>Sensory neuropathy in vasculitis: a clinical, pathologic, and electrophysiologic study</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>5</NO>
<PG>874-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singhal-1995" NAME="Singhal 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singhal BS, Khadilkar SV, Gursahani RD, Surya N</AU>
<TI>Vasculitic neuropathy: profile of twenty patients</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1995</YR>
<VL>43</VL>
<NO>7</NO>
<PG>459-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sobue-1989" NAME="Sobue 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sobue G, Nakao N, Kumazawa K, Mitsuma T</AU>
<TI>[Migrating multiple mononeuritis and nonsystemic angitis]</TI>
<SO>Rinsho Shinkeigaku</SO>
<YR>1989</YR>
<VL>29</VL>
<NO>10</NO>
<PG>1210-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sugiura-2006" NAME="Sugiura 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sugiura M, Koike H, Iijima M, Mori K, Hattori N, Katsuno M, et al</AU>
<TI>Clinicopathologic features of nonsystemic vasculitic neuropathy and microscopic polyangiitis-associated neuropathy: a comparative study</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2006</YR>
<VL>241</VL>
<NO>1-2</NO>
<PG>31-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vincent-1985" NAME="Vincent 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vincent D, Dubas F, Hauw JJ, Escourolle R, Godeau P, Buge A, et al</AU>
<TI>Nerve and muscle microvasculitis: 50 cases</TI>
<TO>Microvasculites nerveuses et musculaires: 50 cas</TO>
<SO>Revue Neurologique (Paris)</SO>
<YR>1985</YR>
<VL>141</VL>
<NO>6-7</NO>
<PG>440-6</PG>
<CY>Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vrancken-2004" NAME="Vrancken 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vrancken AFJE, Notermans NC, Jansen GH, Wokke JHJ, Said G</AU>
<TI>Progressive idiopathic axonal neuropathy: a comparative clinical and histopathological study with vasculitic neuropathy</TI>
<SO>Journal of Neurology</SO>
<YR>2004</YR>
<VL>251</VL>
<NO>3</NO>
<PG>269-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Weisshaar-2002" MODIFIED="2009-05-13 22:20:58 +0100" MODIFIED_BY="[Empty name]" NAME="Weisshaar 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-13 22:20:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Weisshaar HM</AU>
<TI>Non-systemic vasculitic peripheral neuropathy: clinical symptoms, neurophysiology, morphology and disease course</TI>
<TO>Die nicht systemische vaskulitische Neuropathie des peripheren Nervensystems - Klinik, Neurophysiologie, Morphologie und Verlauf</TO>
<SO>Thesis Humboldt-Universität Berlin</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-05-13 22:20:58 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zivkovic-2007" MODIFIED="2009-11-10 17:04:20 +0000" MODIFIED_BY="Ruth Brassington" NAME="Zivkovic 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-10 17:04:20 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zivkovic SA, Ascherman D, Lacomis D</AU>
<TI>Vasculitic neuropathy--electrodiagnostic findings and association with malignancies</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2007</YR>
<VL>115</VL>
<NO>6</NO>
<PG>432-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17511855"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-05-17 20:37:23 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-06-29 11:30:58 +0100" MODIFIED_BY="Ruth Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2011-06-29 11:30:58 +0100" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Abgrall-2001" NAME="Abgrall 2001" TYPE="JOURNAL_ARTICLE">
<AU>Abgrall S, Mouthon L, Cohen P, Authier FJ, Nizou R, Ropert A, et al</AU>
<TI>Localized neurological necrotizing vasculitides. Three cases with isolated mononeuritis multiplex</TI>
<SO>Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>3</NO>
<PG>631-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Agard-2003" NAME="Agard 2003" TYPE="JOURNAL_ARTICLE">
<AU>Agard C, Mouthon L, Mahr A, Guillevin L</AU>
<TI>Microscopic polyangiitis and polyarteritis nodosa: how and when do they start?</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2003</YR>
<VL>49</VL>
<NO>5</NO>
<PG>709-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ali-2007" MODIFIED="2009-05-22 18:02:32 +0100" MODIFIED_BY="[Empty name]" NAME="Ali 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ali Z, Ranganathan P, Perry A, Gelbart M</AU>
<TI>Localized striated muscle vasculitis in rheumatoid arthritis</TI>
<SO>Journal of Clinical Rheumatology</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>1</NO>
<PG>35-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17278948"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Balbir_x002d_Gurman-2007" MODIFIED="2009-05-22 18:03:13 +0100" MODIFIED_BY="[Empty name]" NAME="Balbir-Gurman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Balbir-Gurman A, Nahir AM, Braun-Moscovici Y</AU>
<TI>Intravenous immunoglobulins in polyarteritis nodosa restricted to the limbs: case reports and review of the literature</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>1 Suppl 44</NO>
<PG>S28-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17428360"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Behari-1995" NAME="Behari 1995" TYPE="JOURNAL_ARTICLE">
<AU>Behari M, Garg R, Dinda AK, Ahuja GK</AU>
<TI>Peripheral neuropathy due to small vessel vasculitis</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1995</YR>
<VL>43</VL>
<NO>7</NO>
<PG>495-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosch-2007" MODIFIED="2009-06-14 14:38:22 +0100" MODIFIED_BY="[Empty name]" NAME="Bosch 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bosch X, Guilabert A, Espinosa G, Mirapeix E</AU>
<TI>Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2007</YR>
<VL>298</VL>
<NO>6</NO>
<PG>655-69</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17684188"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bourgarit-2005" NAME="Bourgarit 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bourgarit A, Le Toumelin P, Pagnoux C, Cohen-Tervaert P, Mahr A, Le Guern V, et al. The French Vasculitis Study Group</AU>
<TI>Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients</TI>
<SO>Medicine (Baltimore)</SO>
<YR>2005</YR>
<VL>84</VL>
<NO>5</NO>
<PG>323-30</PG>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braun_x002d_Moscovici-2003a" MODIFIED="2009-11-04 16:21:29 +0000" MODIFIED_BY="Jane Batchelor" NAME="Braun-Moscovici 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Braun-Moscovici Y, Furst DE</AU>
<TI>Plasmapheresis for rheumatic diseases in the twenty-first century: take it or leave it?</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3</NO>
<PG>197-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braun_x002d_Moscovici-2003b" MODIFIED="2009-11-04 16:21:48 +0000" MODIFIED_BY="Jane Batchelor" NAME="Braun-Moscovici 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Braun-Moscovici Y, Furst DE</AU>
<TI>Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it?</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3</NO>
<PG>237-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brockwell-2001" NAME="Brockwell 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brockwell SE, Gordon IR</AU>
<TI>A comparison of statistical methods for meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>6</NO>
<PG>825-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caporali-2004" MODIFIED="2009-05-23 00:59:50 +0100" MODIFIED_BY="[Empty name]" NAME="Caporali 2004" TYPE="JOURNAL_ARTICLE">
<AU>Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, et al</AU>
<TI>Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>141</VL>
<NO>7</NO>
<PG>493-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlson-2007" MODIFIED="2009-06-14 14:38:54 +0100" MODIFIED_BY="[Empty name]" NAME="Carlson 2007" TYPE="JOURNAL_ARTICLE">
<AU>Carlson JA, Chen KR</AU>
<TI>Cutaneous vasculitis update: neutrophilic muscular vessel and eosinophilic, granulomatous, and lymphocytic vasculitis syndromes</TI>
<SO>American Journal of Dermatopathology</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>1</NO>
<PG>32-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17284960"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cattaneo-2007" MODIFIED="2009-11-10 17:24:06 +0000" MODIFIED_BY="Ruth Brassington" NAME="Cattaneo 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cattaneo L, Chierici E, Pavone L, Grasselli C, Manganelli P, Buzio C, et al</AU>
<TI>Peripheral neuropathy in Wegener's granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2007</YR>
<VL>78</VL>
<NO>10</NO>
<PG>1119-23</PG>
<IDENTIFIERS MODIFIED="2009-06-23 22:00:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17299018"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cavallo-2009" MODIFIED="2009-08-01 11:36:55 +0100" MODIFIED_BY="Alexander FJE Vrancken" NAME="Cavallo 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cavallo R, Roccatello D, Menegatti E, Naretto C, Napoli F, Baldovino S</AU>
<TI>Rituximab in cryoglobulinemic peripheral neuropathy</TI>
<SO>Journal of Neurology</SO>
<YR>2009</YR>
<VL>256</VL>
<NO>7</NO>
<PG>1076-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19263187"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chang-1984" NAME="Chang 1984" TYPE="JOURNAL_ARTICLE">
<AU>Chang RW, Bell CL, Hallett M</AU>
<TI>Clinical characteristics and prognosis of vasculitic mononeuropathy multiplex</TI>
<SO>Archives of Neurology</SO>
<YR>1984</YR>
<VL>41</VL>
<NO>6</NO>
<PG>618-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chung-2009" MODIFIED="2009-05-17 00:20:40 +0100" MODIFIED_BY="[Empty name]" NAME="Chung 2009" TYPE="JOURNAL_ARTICLE">
<AU>Chung SA, Seo P</AU>
<TI>Advances in the use of biologic agents for the treatment of systemic vasculitis</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>1</NO>
<PG>3-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19077713"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cimmino-2008" MODIFIED="2009-05-26 14:47:26 +0100" MODIFIED_BY="[Empty name]" NAME="Cimmino 2008" TYPE="JOURNAL_ARTICLE">
<AU>Cimmino MA, Salvarani C, Macchioni P, Gerli R, Bartoloni Bocci E, Montecucco C, et al</AU>
<TI>Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>3</NO>
<PG>395-400</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18578959"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Claussen-2000" NAME="Claussen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Claussen GC, Thomas TD, Goyne C, Vázquez LG, Oh SJ</AU>
<TI>Diagnostic value of nerve and muscle biopsy in suspected vasculitis cases</TI>
<SO>Journal of Clinical Neuromuscular Disease</SO>
<YR>2000</YR>
<VL>1</VL>
<NO>3</NO>
<PG>117-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1980" NAME="Cohen 1980" TYPE="JOURNAL_ARTICLE">
<AU>Cohen RD, Conn DL, Ilstrup DM</AU>
<TI>Clinical features, prognosis, and response to treatment in polyarteritis</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1980</YR>
<VL>55</VL>
<NO>3</NO>
<PG>146-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-2000" NAME="Collins 2000" TYPE="JOURNAL_ARTICLE">
<AU>Collins MP, Mendell JR, Periquet MI, Sahenk Z, Amato AA, Gronseth GS, et al</AU>
<TI>Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>5</NO>
<PG>636-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-2005" MODIFIED="2009-05-22 11:55:52 +0100" MODIFIED_BY="[Empty name]" NAME="Collins 2005" TYPE="JOURNAL_ARTICLE">
<AU>Collins MP</AU>
<TI>Localized vasculitis and the peripheral nervous system</TI>
<SO>Journal of Rheumatology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>5</NO>
<PG>769-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-2008" MODIFIED="2009-05-22 10:21:56 +0100" MODIFIED_BY="[Empty name]" NAME="Collins 2008" TYPE="JOURNAL_ARTICLE">
<AU>Collins MP, Periquet MI</AU>
<TI>Isolated vasculitis of the peripheral nervous system</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>3 Suppl 49</NO>
<PG>S118-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18799069"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collins-2010" MODIFIED="2011-06-29 11:30:28 +0100" MODIFIED_BY="Ruth Brassington" NAME="Collins 2010" TYPE="JOURNAL_ARTICLE">
<AU>Collins MP, Dyck PJ, Gronseth GS, Guillevin L, Hadden RD, Heuss D, et al</AU>
<TI>Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary</TI>
<SO>Journal of the Peripheral Nervous System</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>3</NO>
<PG>176-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21040139"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Danieli-2004" MODIFIED="2009-06-14 23:00:19 +0100" MODIFIED_BY="[Empty name]" NAME="Danieli 2004" TYPE="JOURNAL_ARTICLE">
<AU>Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G</AU>
<TI>Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>12</NO>
<PG>1649-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="15547090"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Groot-2001" MODIFIED="2009-07-19 17:50:04 +0100" MODIFIED_BY="[Empty name]" NAME="de Groot 2001" TYPE="JOURNAL_ARTICLE">
<AU>de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E</AU>
<TI>Standardized neurologic evaluations of 128 patients with Wegener's granulomatosis</TI>
<SO>Archives of Neurology</SO>
<YR>2001</YR>
<VL>58</VL>
<NO>8</NO>
<PG>1215-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Groot-2009" MODIFIED="2009-11-10 17:24:32 +0000" MODIFIED_BY="Ruth Brassington" NAME="de Groot 2009" TYPE="JOURNAL_ARTICLE">
<AU>de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al</AU>
<TI>Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2009</YR>
<VL>150</VL>
<NO>10</NO>
<PG>670-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19451574"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-De-la-Sayette-1995" NAME="De la Sayette 1995" TYPE="JOURNAL_ARTICLE">
<AU>De la Sayette V, Macro M, Diraison P, Bertran F, Lechevalier B, Chapon F</AU>
<TI>Acute necrotizing vasculitis (polyarteritis nodosa?) confined to the nerve with spontaneous recovery [letter]</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1995</YR>
<VL>34</VL>
<NO>7</NO>
<PG>694-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Silva-1986" NAME="De Silva 1986" TYPE="JOURNAL_ARTICLE">
<AU>De Silva M, Hazleman BL</AU>
<TI>Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1986</YR>
<VL>45</VL>
<NO>2</NO>
<PG>136-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deprez-2000" NAME="Deprez 2000" TYPE="JOURNAL_ARTICLE">
<AU>Deprez M, de Groote CC, Gollogly L, Reznik M, Martin JJ</AU>
<TI>Clinical and neuropathological parameters affecting the diagnostic yield of nerve biopsy</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>2</NO>
<PG>92-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dyck-1972" NAME="Dyck 1972" TYPE="JOURNAL_ARTICLE">
<AU>Dyck PJ, Conn DL, Okazaki H</AU>
<TI>Necrotizing angiopathic neuropathy. Three-dimensional morphology of fiber degeneration related to sites of occluded vessels</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1972</YR>
<VL>47</VL>
<NO>7</NO>
<PG>461-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Exley-1997" NAME="Exley 1997" TYPE="JOURNAL_ARTICLE">
<AU>Exley AR, Carruthers DM, Luqmani RA, Kitas GD, Gordon C, Janssen BA, et al</AU>
<TI>Damage occurs early in systemic vasculitis and is an index of outcome</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>1997</YR>
<VL>90</VL>
<NO>6</NO>
<PG>391-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fain-2007" MODIFIED="2009-05-22 18:04:33 +0100" MODIFIED_BY="[Empty name]" NAME="Fain 2007" TYPE="JOURNAL_ARTICLE">
<AU>Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, Paries J, et al</AU>
<TI>Vasculitides associated with malignancies: analysis of sixty patients</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2007</YR>
<VL>57</VL>
<NO>8</NO>
<PG>1473-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18050165"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fauci-1978" NAME="Fauci 1978" TYPE="JOURNAL_ARTICLE">
<AU>Fauci AS, Haynes BF, Katz P</AU>
<TI>The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1978</YR>
<VL>89</VL>
<NO>5 Pt 1</NO>
<PG>660-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fauci-1979" NAME="Fauci 1979" TYPE="JOURNAL_ARTICLE">
<AU>Fauci AS, Katz P, Haynes BF, Wolff SM</AU>
<TI>Cyclophosphamide therapy of severe necrotizing vasculitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1979</YR>
<VL>301</VL>
<NO>5</NO>
<PG>235-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fauci-1983" NAME="Fauci 1983" TYPE="JOURNAL_ARTICLE">
<AU>Fauci AS, Haynes B, Katz P, Wolff S</AU>
<TI>Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1983</YR>
<VL>98</VL>
<NO>1</NO>
<PG>76-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frohnert-1967" NAME="Frohnert 1967" TYPE="JOURNAL_ARTICLE">
<AU>Frohnert PP, Sheps SG</AU>
<TI>Long-term follow-up study of periarteritis nodosa</TI>
<SO>American Journal of Medicine</SO>
<YR>1967</YR>
<VL>43</VL>
<NO>1</NO>
<PG>8-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fujimura-1991" NAME="Fujimura 1991" TYPE="JOURNAL_ARTICLE">
<AU>Fujimura H, Lacroix C, Said G</AU>
<TI>Vulnerability of nerve fibres to ischaemia. A quantitative light and electron microscope study</TI>
<SO>Brain</SO>
<YR>1991</YR>
<VL>114</VL>
<NO>Pt 4</NO>
<PG>1929-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gallien-2002" MODIFIED="2009-05-22 18:05:02 +0100" MODIFIED_BY="[Empty name]" NAME="Gallien 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gallien S, Mahr A, Rety F, Kambouchner M, Lhote F, Cohen P, et al</AU>
<TI>Magnetic resonance imaging of skeletal muscle involvement in limb restricted vasculitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>12</NO>
<PG>1107-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="12429545"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gorson-2006" MODIFIED="2009-05-22 10:21:25 +0100" MODIFIED_BY="[Empty name]" NAME="Gorson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gorson KC</AU>
<TI>Therapy for vasculitic neuropathies</TI>
<SO>Current Treatment Options in Neurology</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>2</NO>
<PG>105-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Graham-2006a" NAME="Graham 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Graham RC, Hughes RAC</AU>
<TI>A modified peripheral neuropathy scale: the overall neuropathy limitations scale</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2006</YR>
<VL>77</VL>
<NO>8</NO>
<PG>973-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Graham-2006b" NAME="Graham 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Graham RC, Hughes RAC</AU>
<TI>Clinimetric properties of a walking scale in peripheral neuropathy</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2006</YR>
<VL>77</VL>
<NO>8</NO>
<PG>977-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenberg-2002" NAME="Greenberg 2002" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg SA</AU>
<TI>P-ANCA vasculitic neuropathy with 12-year latency between onset of neuropathy and systemic symptoms</TI>
<SO>BMC Neurology</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>1</NO>
<PG>10</PG>
<MD>http://www.biomedcentral.com/1471-2377/2/10</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guillevin-1985" NAME="Guillevin 1985" TYPE="JOURNAL_ARTICLE">
<AU>Guillevin L, Fechner J, Godeau P, Bletry O, Wechsler B, Herreman G, et al</AU>
<TI>Periarteritis nodosa: clinical and therapeutic study of 126 patients followed-up during 23 years</TI>
<TO>Periarterite noueuse: étude clinique et thérapeutique de 126 malades étudiés en 23 ans</TO>
<SO>Annales de Médecine Interne (Paris)</SO>
<YR>1985</YR>
<VL>136</VL>
<NO>1</NO>
<PG>6-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guillevin-2007" MODIFIED="2009-05-22 17:57:39 +0100" MODIFIED_BY="[Empty name]" NAME="Guillevin 2007" TYPE="JOURNAL_ARTICLE">
<AU>Guillevin L, Pagnoux C</AU>
<TI>Indication for plasma exchange for systemic necrotizing vasculidities</TI>
<SO>Transfusion and Apheresis Science</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>2</NO>
<PG>179-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17499762"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hattori-1999" NAME="Hattori 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hattori N, Ichimura M, Nagamatsu M, Li M, Yamamoto K, Kumazawa K, Mitsuma T, et al</AU>
<TI>Clinicopathological features of Churg-Strauss syndrome-associated neuropathy</TI>
<SO>Brain</SO>
<YR>1999</YR>
<VL>122</VL>
<NO>Pt 3</NO>
<PG>427-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hattori-2002" NAME="Hattori 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hattori N, Mori K, Misu K, Koike H, Ichimura M, Sobue G</AU>
<TI>Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>7</NO>
<PG>1408-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hernandez_x002d_Rodriguez-2008" MODIFIED="2009-11-10 17:25:03 +0000" MODIFIED_BY="Ruth Brassington" NAME="Hernandez-Rodriguez 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hernandez-Rodriguez J, Molloy ES, Hoffman GS</AU>
<TI>Single-organ vasculitis</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>1</NO>
<PG>40-6</PG>
<IDENTIFIERS MODIFIED="2009-06-23 22:14:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18281856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heurkens-1991" NAME="Heurkens 1991" TYPE="JOURNAL_ARTICLE">
<AU>Heurkens AH, Westedt ML, Breedveld FC</AU>
<TI>Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1991</YR>
<VL>151</VL>
<NO>11</NO>
<PG>2249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heuss-2003" MODIFIED="2009-05-17 21:01:32 +0100" MODIFIED_BY="[Empty name]" NAME="Heuss 2003" TYPE="JOURNAL_ARTICLE">
<AU>Heuss D, Schlotter-Weigel B, Sommer C</AU>
<TI>Diagnosis and therapy of vasculitic neuropathy. Consensus statement of the German Centers for Neuromuscular Disease</TI>
<TO>Klinik, Diagnostik und Therapie der vaskulitischen Neuropathie. Bundeseinheitliche Konsensuspapiere der Muskelzentren im Auftrag der Deutschen Gesellschaft für Muskelkranke e.V. (DGM)</TO>
<SO>Fortschritte der Neurologie · Psychiatrie</SO>
<YR>2003</YR>
<VL>71</VL>
<NO>4</NO>
<PG>172-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-11-10 17:25:27 +0000" MODIFIED_BY="Ruth Brassington" NAME="Higgins 2008" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2009-11-04 16:24:45 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Hu-2008" MODIFIED="2009-05-22 18:05:40 +0100" MODIFIED_BY="[Empty name]" NAME="Hu 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hu W, Liu C, Xie H, Chen H, Liu Z, Li L</AU>
<TI>Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement</TI>
<SO>Nephrology, Dialysis and Transplantation</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>4</NO>
<PG>1307-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18065810"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2008" MODIFIED="2009-11-10 17:25:46 +0000" MODIFIED_BY="Ruth Brassington" NAME="Hughes 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hughes R</AU>
<TI>The role of IVIg in autoimmune neuropathies: the latest evidence</TI>
<SO>Journal of Neurology</SO>
<YR>2008</YR>
<VL>255 Suppl 3</VL>
<PG>7-11</PG>
<IDENTIFIERS MODIFIED="2009-06-14 22:47:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18685920"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Iaccarino-2007" MODIFIED="2009-06-14 22:13:51 +0100" MODIFIED_BY="[Empty name]" NAME="Iaccarino 2007" TYPE="JOURNAL_ARTICLE">
<AU>Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A</AU>
<TI>Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?</TI>
<SO>Autoimmunity reviews</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>3</NO>
<PG>190-5</PG>
<IDENTIFIERS MODIFIED="2009-06-14 22:13:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17289556"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jayne-2003" NAME="Jayne 2003" TYPE="JOURNAL_ARTICLE">
<AU>Jayne D, Rasmussen N, Andrassy K, Bacon P, Cohen-Tervaert JW, Dadoniené J, et al</AU>
<TI>A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>1</NO>
<PG>36-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jayne-2008" MODIFIED="2009-05-17 00:22:43 +0100" MODIFIED_BY="[Empty name]" NAME="Jayne 2008" TYPE="JOURNAL_ARTICLE">
<AU>Jayne D</AU>
<TI>Challenges in the management of microscopic polyangiitis: past, present and future</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>1</NO>
<PG>3-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18281850"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jennette-1997" NAME="Jennette 1997" TYPE="JOURNAL_ARTICLE">
<AU>Jennette JC, Falk RJ</AU>
<TI>Small-vessel vasculitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<NO>21</NO>
<PG>1512-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kallenberg-2008" MODIFIED="2009-05-22 10:23:16 +0100" MODIFIED_BY="[Empty name]" NAME="Kallenberg 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kallenberg CG</AU>
<TI>The last classification of vasculitis</TI>
<SO>Clinical Reviews in Allergy &amp; Immunology</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>1-2</NO>
<PG>5-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18172778"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kamimura-2005" NAME="Kamimura 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kamimura T, Hatakeyama M, Torigoe K, Nara H, Kaneko N, Satou H, et al</AU>
<TI>Muscular polyarteritis nodosa as a cause of fever of undetermined origin: a case report and review of the literature</TI>
<SO>Rheumatology International</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>5</NO>
<PG>394-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kazderova-2008" MODIFIED="2009-06-14 22:13:51 +0100" MODIFIED_BY="[Empty name]" NAME="Kazderova 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kazderova M, Jancova E, Rysava R, Merta M, Tesar V</AU>
<TI>Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis</TI>
<SO>Archives of medical research</SO>
<YR>2008</YR>
<VL>39</VL>
<NO>1</NO>
<PG>115-9</PG>
<IDENTIFIERS MODIFIED="2009-06-14 22:13:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18068004"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kernohan-1938" NAME="Kernohan 1938" TYPE="JOURNAL_ARTICLE">
<AU>Kernohan JW, Woltman HW</AU>
<TI>Periarteritis nodosa. A clinicopathologic study with special reference to the nervous system</TI>
<SO>Archives of Neurology and Psychiatry</SO>
<YR>1938</YR>
<VL>39</VL>
<NO>4</NO>
<PG>655-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khellaf-2007" MODIFIED="2009-05-22 23:48:41 +0100" MODIFIED_BY="[Empty name]" NAME="Khellaf 2007" TYPE="JOURNAL_ARTICLE">
<AU>Khellaf M, Hamidou M, Pagnoux C, Michel M, Brisseau JM, Chevallier X, et al</AU>
<TI>Vasculitis restricted to the lower limbs: a clinical and histopathological study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66</VL>
<NO>4</NO>
<PG>554-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17068062"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kuntzer-1995" NAME="Kuntzer 1995" TYPE="JOURNAL_ARTICLE">
<AU>Kuntzer T, Magistris MR</AU>
<TI>Conduction blocks and peripheral neuropathies</TI>
<TO>Blocs de conduction et neuropathies périphériques</TO>
<SO>Revue Neurologique (Paris)</SO>
<YR>1995</YR>
<VL>151</VL>
<NO>6-7</NO>
<PG>368-82</PG>
<CY>Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lacomis-1997" NAME="Lacomis 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lacomis D, Giuliani MJ, Steen V, Powell HC</AU>
<TI>Small fiber neuropathy and vasculitis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1997</YR>
<VL>40</VL>
<NO>6</NO>
<PG>1173-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langford-2005" NAME="Langford 2005" TYPE="JOURNAL_ARTICLE">
<AU>Langford CA</AU>
<TI>How can relapses be detected and prevented in primary systemic small-vessel vasculitides?</TI>
<SO>Best Practice &amp; Research Clinical Rheumatology</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>2</NO>
<PG>307-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Larrod_x00e9_-1997" NAME="Larrodé 1997" TYPE="JOURNAL_ARTICLE">
<AU>Larrodé P, Ramon y Cajal S, Iñíguez C, Dominguez M, Sanz JM, Morales F</AU>
<TI>Isolated vasculitis of the peripheral nervous system</TI>
<TO>Vasculitis aislada del sistema nervioso periférico (VASNP)</TO>
<SO>Neurología (Barcelona)</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>5</NO>
<PG>197-9</PG>
<CY>Barcelona</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leib-1979" NAME="Leib 1979" TYPE="JOURNAL_ARTICLE">
<AU>Leib ES, Restivo C, Paulus HE</AU>
<TI>Immunosuppressive and corticosteroid therapy of polyarteritis nodosa</TI>
<SO>American Journal of Medicine</SO>
<YR>1979</YR>
<VL>67</VL>
<NO>6</NO>
<PG>941-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levy-1999" NAME="Levy 1999" TYPE="JOURNAL_ARTICLE">
<AU>Levy Y, Sherer Y, George J, Langevitz P, Ahmed A, Bar-Dayan Y, et al</AU>
<TI>Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin</TI>
<SO>International Archives of Allergy &amp; Immunology</SO>
<YR>1999</YR>
<VL>119</VL>
<NO>3</NO>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levy-2005" NAME="Levy 2005" TYPE="JOURNAL_ARTICLE">
<AU>Levy Y, Uziel Y, Zandman G, Rotman P, Amital H, Sherer Y, et al</AU>
<TI>Response of vasculitic peripheral neuropathy to intravenous immunoglobulin</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2005</YR>
<VL>1051</VL>
<PG>779-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lie-1997" NAME="Lie 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lie JT</AU>
<TI>Biopsy diagnosis of systemic vasculitis</TI>
<SO>Baillière's Clinical Rheumatology</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>2</NO>
<PG>219-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lovric-2009" MODIFIED="2009-06-14 22:49:39 +0100" MODIFIED_BY="[Empty name]" NAME="Lovric 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lovric S, Erdbruegger U, Kumpers P, Woywodt A, Koenecke C, Wedemeyer H, et al</AU>
<TI>Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients</TI>
<SO>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>1</NO>
<PG>179-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18685144"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marder-2004" NAME="Marder 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marder W, McCune WJ</AU>
<TI>Advances in immunosuppressive drug therapy for use in autoimmune disease and systemic vasculitis</TI>
<SO>Seminars in Respiratory and Critical Care Medicine</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>5</NO>
<PG>581-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martin-2007" MODIFIED="2009-05-23 20:43:39 +0100" MODIFIED_BY="[Empty name]" NAME="Martin 2007" TYPE="JOURNAL_ARTICLE">
<AU>Martin K, Bentaberry F, Dumoulin C, Miremont-Salame G, Haramburu F, Dehais J, et al</AU>
<TI>Peripheral neuropathy associated with leflunomide: is there a risk patient profile?</TI>
<SO>Pharmacoepidemiology and Drug Safety</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>1</NO>
<PG>74-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16845649"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martinez-2008" MODIFIED="2009-06-14 22:58:44 +0100" MODIFIED_BY="[Empty name]" NAME="Martinez 2008" TYPE="JOURNAL_ARTICLE">
<AU>Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al</AU>
<TI>Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2008</YR>
<VL>58</VL>
<NO>1</NO>
<PG>308-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18163506"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martinez_x002d_Taboada-2008" MODIFIED="2009-05-17 00:23:39 +0100" MODIFIED_BY="[Empty name]" NAME="Martinez-Taboada 2008" TYPE="JOURNAL_ARTICLE">
<AU>Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, Lopez-Longo J, Figueroa M, Belzunegui J, et al</AU>
<TI>A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2008</YR>
<VL>67</VL>
<NO>5</NO>
<PG>625-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18086726"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McCluskey-1999" NAME="McCluskey 1999" TYPE="JOURNAL_ARTICLE">
<AU>McCluskey L, Feinberg D, Cantor C, Bird S</AU>
<TI>"Pseudo-conduction block" in vasculitic neuropathy</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>10</NO>
<PG>1361-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merkies-2003" NAME="Merkies 2003" TYPE="JOURNAL_ARTICLE">
<AU>Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA</AU>
<TI>Connecting impairment, disability, and handicap in immune mediated polyneuropathies</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2003</YR>
<VL>74</VL>
<NO>1</NO>
<PG>99-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merkies-2006" NAME="Merkies 2006" TYPE="JOURNAL_ARTICLE">
<AU>Merkies ISJ, Schmitz PI</AU>
<TI>Getting closer to patients: the INCAT overall disability sumscore relates better to patients' own clinical judgment in immune-mediated polyneuropathies</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2006</YR>
<VL>77</VL>
<NO>8</NO>
<PG>970-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Metzler-2007" MODIFIED="2009-05-16 23:26:33 +0100" MODIFIED_BY="[Empty name]" NAME="Metzler 2007" TYPE="JOURNAL_ARTICLE">
<AU>Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, et al</AU>
<TI>Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2007</YR>
<VL>46</VL>
<NO>7</NO>
<PG>1087-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17519271"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Molyneux-2000" NAME="Molyneux 2000" TYPE="JOURNAL_ARTICLE">
<AU>Molyneux PD, Barker R, Thomas PK, King RH, Miller DH</AU>
<TI>Non-systemic vasculitic neuropathy presenting with a painful polyradiculopathy: a case report [letter]</TI>
<SO>Journal of Neurology</SO>
<YR>2000</YR>
<VL>247</VL>
<NO>8</NO>
<PG>645-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1981" NAME="Moore 1981" TYPE="JOURNAL_ARTICLE">
<AU>Moore PM, Fauci AS</AU>
<TI>Neurologic manifestations of systemic vasculitis. A retrospective and prospective study of the clinicopathologic features and responses to therapy</TI>
<SO>American Journal of Medicine</SO>
<YR>1981</YR>
<VL>71</VL>
<NO>4</NO>
<PG>517-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mori-2005" NAME="Mori 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al</AU>
<TI>The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy</TI>
<SO>Brain</SO>
<YR>2005</YR>
<VL>128</VL>
<NO>Pt 11</NO>
<PG>2518-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mouthon-2002" NAME="Mouthon 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mouthon L, Le Toumelin P, André MH, Gayraud M, Casassus P, Guillevin L</AU>
<TI>Polyarteritis nodosa and Churg-Strauss angiitis. Characteristics and outcome in 38 patients over 65 years</TI>
<SO>Medicine (Baltimore)</SO>
<YR>2002</YR>
<VL>81</VL>
<NO>1</NO>
<PG>27-40</PG>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mukhtyar-2008" MODIFIED="2009-05-17 00:24:14 +0100" MODIFIED_BY="[Empty name]" NAME="Mukhtyar 2008" TYPE="JOURNAL_ARTICLE">
<AU>Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al</AU>
<TI>Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2008</YR>
<VL>67</VL>
<NO>7</NO>
<PG>1004-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17911225"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mukhtyar-2009a" MODIFIED="2009-06-14 21:49:18 +0100" MODIFIED_BY="[Empty name]" NAME="Mukhtyar 2009a" TYPE="JOURNAL_ARTICLE">
<AU>Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al</AU>
<TI>EULAR recommendations for the management of large vessel vasculitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2009</YR>
<VL>68</VL>
<NO>3</NO>
<PG>318-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18413441"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mukhtyar-2009b" MODIFIED="2009-06-14 21:49:31 +0100" MODIFIED_BY="[Empty name]" NAME="Mukhtyar 2009b" TYPE="JOURNAL_ARTICLE">
<AU>Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al</AU>
<TI>EULAR recommendations for the management of primary small and medium vessel vasculitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2009</YR>
<VL>68</VL>
<NO>3</NO>
<PG>310-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18413444"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nachman-1996" NAME="Nachman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Nachman PH, Hogan SL, Jennette JC, Falk RJ</AU>
<TI>Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>1</NO>
<PG>33-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nakamura-2003" NAME="Nakamura 2003" TYPE="JOURNAL_ARTICLE">
<AU>Nakamura T, Tomoda K, Yamamura Y, Tsukano M, Honda I, Iyama K</AU>
<TI>Polyarteritis nodosa limited to calf muscles: a case report and review of the literature</TI>
<SO>Clinical Rheumatology</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>2</NO>
<PG>149-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nakamura-2009" MODIFIED="2009-05-22 11:26:33 +0100" MODIFIED_BY="[Empty name]" NAME="Nakamura 2009" TYPE="JOURNAL_ARTICLE">
<AU>Nakamura T, Kanazawa N, Ikeda T, Yamamoto Y, Nakabayashi K, Ozaki S, et al</AU>
<TI>Cutaneous polyarteritis nodosa: revisiting its definition and diagnostic criteria</TI>
<SO>Archives of Dermatological Research</SO>
<YR>2009</YR>
<VL>301</VL>
<NO>1</NO>
<PG>117-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18802715"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nemni-2003" MODIFIED="2009-06-14 14:56:29 +0100" MODIFIED_BY="[Empty name]" NAME="Nemni 2003" TYPE="JOURNAL_ARTICLE">
<AU>Nemni R, Sanvito L, Quattrini A, Santuccio G, Camerlingo M, Canal N</AU>
<TI>Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2003</YR>
<VL>74</VL>
<NO>9</NO>
<PG>1267-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="12933932"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nicholls-1973" MODIFIED="2009-11-04 16:25:40 +0000" MODIFIED_BY="Jane Batchelor" NAME="Nicholls 1973" TYPE="JOURNAL_ARTICLE">
<AU>Nicholls A, Snaith ML, Maini RN, Scott JT</AU>
<TI>Controlled trial of azathioprine in rheumatoid vasculitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1973</YR>
<VL>32</VL>
<NO>6</NO>
<PG>589-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nukada-1987" NAME="Nukada 1987" TYPE="JOURNAL_ARTICLE">
<AU>Nukada H, Dyck PJ</AU>
<TI>Acute ischemia causes axonal stasis, swelling, attenuation, and secondary demyelination</TI>
<SO>Annals of Neurology</SO>
<YR>1987</YR>
<VL>22</VL>
<NO>3</NO>
<PG>311-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nukada-1996" NAME="Nukada 1996" TYPE="JOURNAL_ARTICLE">
<AU>Nukada H, van Rij AM, Packer SG, McMorran PD</AU>
<TI>Pathology of acute and chronic ischaemic neuropathy in atherosclerotic peripheral vascular disease</TI>
<SO>Brain</SO>
<YR>1996</YR>
<VL>119</VL>
<NO>Pt 5</NO>
<PG>1449-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oh-1990" MODIFIED="2009-05-26 13:33:19 +0100" MODIFIED_BY="[Empty name]" NAME="Oh 1990" TYPE="JOURNAL_ARTICLE">
<AU>Oh SJ</AU>
<TI>Diagnostic usefulness and limitations of the sural nerve biopsy</TI>
<SO>Yonsei Medical Journal</SO>
<YR>1990</YR>
<VL>31</VL>
<NO>1</NO>
<PG>1-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oh-1997" NAME="Oh 1997" TYPE="JOURNAL_ARTICLE">
<AU>Oh SJ</AU>
<TI>Paraneoplastic vasculitis of the peripheral nervous system</TI>
<SO>Neurologic Clinics</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>4</NO>
<PG>849-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pagnoux-2004" MODIFIED="2009-05-17 20:59:56 +0100" MODIFIED_BY="[Empty name]" NAME="Pagnoux 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pagnoux C, Guillevin L</AU>
<TI>Peripheral neuropathy in systemic vasculitides</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>1</NO>
<PG>41-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pagnoux-2008" MODIFIED="2009-06-14 14:41:05 +0100" MODIFIED_BY="[Empty name]" NAME="Pagnoux 2008" TYPE="JOURNAL_ARTICLE">
<AU>Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al</AU>
<TI>Azathioprine or methotrexate maintenance for ANCA-associated vasculitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>359</VL>
<NO>26</NO>
<PG>2790-803</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19109574"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pavesi-1987" MODIFIED="2009-06-14 14:41:18 +0100" MODIFIED_BY="[Empty name]" NAME="Pavesi 1987" TYPE="JOURNAL_ARTICLE">
<AU>Pavesi G, Gemignani F, Manganelli P, Mancia D, Marbini A</AU>
<TI>Polyneuropathy and systemic vasculitis. An electrophysiological study</TI>
<SO>Italian Journal of Neurological Sciences</SO>
<YR>1987</YR>
<VL>8</VL>
<NO>2</NO>
<PG>171-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pipitone-2008" MODIFIED="2009-05-22 11:25:51 +0100" MODIFIED_BY="[Empty name]" NAME="Pipitone 2008" TYPE="JOURNAL_ARTICLE">
<AU>Pipitone N, Salvarani C</AU>
<TI>Improving therapeutic options for patients with giant cell arteritis</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>1</NO>
<PG>17-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18281852"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Prineas-1970" MODIFIED="2009-11-04 16:31:35 +0000" MODIFIED_BY="Jane Batchelor" NAME="Prineas 1970" TYPE="JOURNAL_ARTICLE">
<AU>Prineas J</AU>
<TI>Polyneuropathies of undetermined cause</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1970</YR>
<VL>44</VL>
<PG>3-72</PG>
<IDENTIFIERS MODIFIED="2009-11-04 16:31:35 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Pu_x00e9_chal-1999" NAME="Puéchal 1999" TYPE="JOURNAL_ARTICLE">
<AU>Puéchal X, Said G</AU>
<TI>Necrotizing vasculitis of the peripheral nervous system: nonsystemic or clinically undetectable? [letter]</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>4</NO>
<PG>824-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quinet-2003" MODIFIED="2009-05-22 10:24:15 +0100" MODIFIED_BY="[Empty name]" NAME="Quinet 2003" TYPE="JOURNAL_ARTICLE">
<AU>Quinet RJ, Zakem JM, McCain M</AU>
<TI>Localized versus systemic vasculitis: diagnosis and management</TI>
<SO>Current Rheumatology Reports</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>2</NO>
<PG>93-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rell_x002d_Bakalarska-1998" NAME="Rell-Bakalarska 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rell-Bakalarska M, Filipowicz-Sosnowska A, Garwolinska H, Zabek J</AU>
<TI>Assessment of the results of combined treatment with cyclophosphamide and prednisone or methotrexate and prednisone in patients with rheumatoid arthritis with concomitant vasculitis</TI>
<SO>Reumatologia</SO>
<YR>1998</YR>
<VL>36</VL>
<NO>1</NO>
<PG>15-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ribi-2008" MODIFIED="2009-05-17 00:24:52 +0100" MODIFIED_BY="[Empty name]" NAME="Ribi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Lauque D, et al</AU>
<TI>Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2008</YR>
<VL>58</VL>
<NO>2</NO>
<PG>586-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18240234"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Richards-2007" MODIFIED="2009-05-23 20:43:52 +0100" MODIFIED_BY="[Empty name]" NAME="Richards 2007" TYPE="JOURNAL_ARTICLE">
<AU>Richards BL, Spies J, McGill N, Richards GW, Vaile J, Bleasel JF, et al</AU>
<TI>Effect of leflunomide on the peripheral nerves in rheumatoid arthritis</TI>
<SO>Internal Medicine Journal</SO>
<YR>2007</YR>
<VL>37</VL>
<NO>2</NO>
<PG>101-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17229252"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ropert-1990" NAME="Ropert 1990" TYPE="JOURNAL_ARTICLE">
<AU>Ropert A, Metral S</AU>
<TI>Conduction block in neuropathies with necrotizing vasculitis</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>2</NO>
<PG>102-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenbaum-2001" MODIFIED="2009-05-17 21:00:04 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenbaum 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rosenbaum RB</AU>
<TI>Neuromuscular complications of connective tissue diseases</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>2</NO>
<PG>154-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Said-2002" NAME="Said 2002" TYPE="JOURNAL_ARTICLE">
<AU>Said G, Lacroix C, Planté-Bordeneuve V, Le Page L, Pico F, Presles O, et al</AU>
<TI>Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients</TI>
<SO>Brain</SO>
<YR>2002</YR>
<VL>125</VL>
<NO>Pt 2</NO>
<PG>264-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Said-2005" MODIFIED="2009-05-17 20:58:32 +0100" MODIFIED_BY="[Empty name]" NAME="Said 2005" TYPE="JOURNAL_ARTICLE">
<AU>Said G, Lacroix C</AU>
<TI>Primary and secondary vasculitic neuropathy</TI>
<SO>Journal of Neurology</SO>
<YR>2005</YR>
<VL>252</VL>
<NO>6</NO>
<PG>633-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Said-2007" MODIFIED="2009-06-14 14:56:35 +0100" MODIFIED_BY="[Empty name]" NAME="Said 2007" TYPE="JOURNAL_ARTICLE">
<AU>Said G</AU>
<TI>Infectious neuropathies</TI>
<SO>Neurologic Clinics</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>1</NO>
<PG>115-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17324723"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Salvarani-2008" MODIFIED="2009-05-22 10:24:39 +0100" MODIFIED_BY="[Empty name]" NAME="Salvarani 2008" TYPE="OTHER">
<AU>Salvarani C, Pipitone N, Boiardi L, Hunder GG</AU>
<TI>Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2008</YR>
<VL>67</VL>
<NO>5</NO>
<PG>577-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18408108"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sanada-2003" NAME="Sanada 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sanada M, Terada M, Suzuki E, Kashiwagi A, Yasuda H</AU>
<TI>MR angiography for the evaluation of non-systemic vasculitic neuropathy</TI>
<SO>Acta Radiologica</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>3</NO>
<PG>316-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schaublin-2005" MODIFIED="2009-05-17 20:58:40 +0100" MODIFIED_BY="[Empty name]" NAME="Schaublin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Schaublin GA, Michet CJ Jr, Dyck PJ, Burns TM</AU>
<TI>An update on the classification and treatment of vasculitic neuropathy</TI>
<SO>Lancet Neurology</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>12</NO>
<PG>853-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schaufelberger-2006" MODIFIED="2009-06-14 21:36:28 +0100" MODIFIED_BY="[Empty name]" NAME="Schaufelberger 2006" TYPE="OTHER">
<AU>Schaufelberger C, Mollby H, Uddhammar A, Bratt J, Nordborg E</AU>
<TI>No additional steroid-sparing effect of cyclosporine A in giant cell arteritis</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2006</YR>
<VL>35</VL>
<NO>4</NO>
<PG>327-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16882602"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Scott-1984" NAME="Scott 1984" TYPE="JOURNAL_ARTICLE">
<AU>Scott DGI, Bacon PA</AU>
<TI>Intravenous cyclophosphamide plus methylprednisolone in the treatment of systemic rheumatoid vasculitis</TI>
<SO>American Journal of Medicine</SO>
<YR>1984</YR>
<VL>76</VL>
<NO>3</NO>
<PG>377-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Selga-2006" MODIFIED="2009-05-17 00:26:50 +0100" MODIFIED_BY="[Empty name]" NAME="Selga 2006" TYPE="JOURNAL_ARTICLE">
<AU>Selga D, Mohammad A, Sturfelt G, Segelmark M</AU>
<TI>Polyarteritis nodosa when applying the Chapel Hill nomenclature - descriptive study on ten patients</TI>
<SO>Rheumatology</SO>
<YR>2006</YR>
<VL>45</VL>
<NO>10</NO>
<PG>1276-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seo-P-2005" MODIFIED="2009-06-14 21:44:15 +0100" MODIFIED_BY="[Empty name]" NAME="Seo P 2005" TYPE="JOURNAL_ARTICLE">
<AU>Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al</AU>
<TI>Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>7</NO>
<PG>2168-78</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="15986348"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shehata-2002" NAME="Shehata 2002" TYPE="JOURNAL_ARTICLE">
<AU>Shehata N, Kouroukis C, Kelton JG</AU>
<TI>A review of randomized controlled trials using therapeutic apheresis</TI>
<SO>Transfusion Medicine Reviews</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>3</NO>
<PG>200-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steinbrecher-2006" MODIFIED="2009-06-14 22:59:49 +0100" MODIFIED_BY="[Empty name]" NAME="Steinbrecher 2006" TYPE="JOURNAL_ARTICLE">
<AU>Steinbrecher A, Berlit P</AU>
<TI>Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders</TI>
<SO>Journal of Neurology</SO>
<YR>2006</YR>
<VL>253 Suppl 5</VL>
<PG>V39-49</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16998753"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-St_x00fc_bgen-2008a" MODIFIED="2009-06-14 22:06:50 +0100" MODIFIED_BY="[Empty name]" NAME="Stübgen 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Stübgen JP</AU>
<TI>Tumor necrosis factor-alpha antagonists and neuropathy</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2008</YR>
<VL>37</VL>
<NO>3</NO>
<PG>281-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18041052"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-St_x00fc_bgen-2008b" MODIFIED="2009-06-14 22:06:57 +0100" MODIFIED_BY="[Empty name]" NAME="Stübgen 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Stübgen JP</AU>
<TI>B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders</TI>
<SO>Journal of Neuroimmunology</SO>
<YR>2008</YR>
<VL>204</VL>
<NO>1-2</NO>
<PG>1-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18783837"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-S_x00e1_nchez-2001" MODIFIED="2009-06-14 14:50:03 +0100" MODIFIED_BY="[Empty name]" NAME="Sánchez 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sánchez J, Coll-Cantí J, Ariza A, Olivé A, Cuixart A, Teixidó J</AU>
<TI>Neuropathy due to necrotizing vasculitis: a study of characteristics and those of the clinical cause of the anatomical and neurophysiological disorder in 26 patients</TI>
<TO>Neuropatía por vasculitis necrotizante: estudio anatomoclínico y neurofisiológico y evolución terapéutica de 26 pacientes</TO>
<SO>Revista de Neurología</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1033-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taniguchi-2007" MODIFIED="2009-06-14 22:59:09 +0100" MODIFIED_BY="[Empty name]" NAME="Taniguchi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Taniguchi M, Tsurikisawa N, Higashi N, Saito H, Mita H, Mori A, et al</AU>
<TI>Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy</TI>
<SO>Allergology International</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>2</NO>
<PG>97-103</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17460439"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tsunemi-1999" NAME="Tsunemi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Tsunemi T, Yokota T, Kikyo H, Yamamoto M, Yamada M, Kobayashi T, et al</AU>
<TI>Nonsystemic vasculitic neuropathy presenting with truncal segmental sensory disturbance and hyperhidrosis</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>5</NO>
<PG>646-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsurikisawa-2004" NAME="Tsurikisawa 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, et al</AU>
<TI>Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin</TI>
<SO>Annals of Allergy Asthma and Immunology</SO>
<YR>2004</YR>
<VL>92</VL>
<NO>1</NO>
<PG>80-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Veen-1996" NAME="van der Veen 1996" TYPE="JOURNAL_ARTICLE">
<AU>van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW</AU>
<TI>Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1996</YR>
<VL>55</VL>
<NO>4</NO>
<PG>218-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Houwelingen-2002" NAME="van Houwelingen 2002" TYPE="JOURNAL_ARTICLE">
<AU>van Houwelingen HC, Arends LR, Stijnen T</AU>
<TI>Advanced methods in meta-analysis: multivariate approach and meta-regression</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>4</NO>
<PG>589-624</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vital-2006" NAME="Vital 2006" TYPE="JOURNAL_ARTICLE">
<AU>Vital C, Vital A, Canron MH, Jaffre A, Viallard JF, Ragnaud JM, et al</AU>
<TI>Combined nerve and muscle biopsy in the diagnosis of vasculitic neuropathy. A 16-year retrospective study of 202 cases</TI>
<SO>Journal of the Peripheral Nervous System</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>1</NO>
<PG>20-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vital-2008" MODIFIED="2009-05-22 11:25:04 +0100" MODIFIED_BY="[Empty name]" NAME="Vital 2008" TYPE="JOURNAL_ARTICLE">
<AU>Vital A, Lagueny A, Ferrer X, Louiset P, Canron MH, Vital C</AU>
<TI>Sarcoid neuropathy: clinico-pathological study of 4 new cases and review of the literature</TI>
<SO>Clinical Neuropathology</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>2</NO>
<PG>96-105</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18402389"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vrancken-2011" MODIFIED="2011-06-29 11:30:58 +0100" MODIFIED_BY="Ruth Brassington" NAME="Vrancken 2011" TYPE="JOURNAL_ARTICLE">
<AU>Vrancken AF, Gathier CS, Cats EA, Notermans NC, Collins MP</AU>
<TI>The additional yield of combined nerve/muscle biopsy in vasculitic neuropathy</TI>
<SO>European Journal of Neurology</SO>
<YR>2011</YR>
<VL>18</VL>
<NO>1</NO>
<PG>49-58</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20482601"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walters-2008" MODIFIED="2009-09-02 14:55:39 +0100" MODIFIED_BY="Ruth Brassington" NAME="Walters 2008" TYPE="COCHRANE_REVIEW">
<AU>Walters G, Willis NS, Craig JC</AU>
<TI>Interventions for renal vasculitis in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-09-02 14:55:39 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2009-09-02 14:55:31 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD003232.pub2"/>
<IDENTIFIER MODIFIED="2009-09-02 14:55:39 +0100" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="18646089"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WGET-Research-Group-2005" MODIFIED="2011-05-23 11:13:43 +0100" MODIFIED_BY="Ruth Brassington" NAME="WGET Research Group 2005" TYPE="JOURNAL_ARTICLE">
<AU>The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group</AU>
<TI>Etanercept plus standard therapy for Wegener's granulomatosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<NO>4</NO>
<PG>351-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiik-2008" MODIFIED="2009-06-14 14:34:05 +0100" MODIFIED_BY="[Empty name]" NAME="Wiik 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wiik A</AU>
<TI>Drug-induced vasculitis</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>1</NO>
<PG>35-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18281855"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Younger-2004" MODIFIED="2009-05-17 21:16:21 +0100" MODIFIED_BY="[Empty name]" NAME="Younger 2004" TYPE="JOURNAL_ARTICLE">
<AU>Younger DS</AU>
<TI>Vasculitis of the nervous system</TI>
<SO>Current Opinion in Neurology</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>3</NO>
<PG>317-36</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2011-02-07 15:58:11 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-07-06 14:52:14 +0100" MODIFIED_BY="Ruth Brassington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-07-06 14:52:14 +0100" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:20:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cartier-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:20:07 +0100" MODIFIED_BY="[Empty name]">
<P>A retrospective study of cases with vasculitic mononeuropathy multiplex, including a few cases with non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:25:52 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Collins-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:25:52 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective cohort and follow-up study of non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:25:58 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Davies-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:25:58 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective and follow-up study describing consecutive cases with non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:52:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dyck-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:52:30 +0100" MODIFIED_BY="[Empty name]">
<P>A retrospective study of consecutive cases with non-systemic vasculitic neuropathy. Treatment was open and uncontrolled and not sufficiently systematic to permit evaluation of efficacy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:07:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dyck-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:07:42 +0100" MODIFIED_BY="[Empty name]">
<P>A retrospective and prospective study of consecutive cases with diabetic and non-diabetic lumbosacral radiculoplexus neuropathy. Microvasculitis was present in nerve biopsies, although not all cases had a nerve biopsy. Several cases received open, uncontrolled treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:18:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dyck-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:18:26 +0100" MODIFIED_BY="[Empty name]">
<P>An open, uncontrolled trial of intravenous methylprednisolone in non-diabetic lumbosacral radiculoplexus neuropathy. Whether a nerve biopsy was performed or not is unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 19:06:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garc_x00e9_s-S_x00e1_nchez-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 19:06:49 +0100" MODIFIED_BY="[Empty name]">
<P>A retrospective study of consecutive cases with non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:27:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Handa-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:27:39 +0100" MODIFIED_BY="[Empty name]">
<P>A study comparing the clinicopathological features and outcome to open and uncontrolled treatment in classical polyarteritis nodosa (PAN) and microscopic polyangiitis. The study included one case with PAN restricted to the peripheral nerves.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 19:07:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harati-1986a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 19:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>A retrospective study of consecutive cases with systemic and non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:26:03 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Hawke-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:26:03 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective and follow-up study of consecutive cases with systemic and non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-06 14:52:14 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Kararizou-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-06 14:52:14 +0100" MODIFIED_BY="Ruth Brassington">
<P>A retrospective study of consecutive cases with non-systemic vasculitic neuropathy. Treatment was open and uncontrolled. Follow-up was not sufficiently systematic to permit evaluation of treatment efficacy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:12:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelkar-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:12:31 +0100" MODIFIED_BY="[Empty name]">
<P>A retrospective clinicopathological study of consecutive cases with idiopathic sensory neuropathy and microvasculitis in sural nerve biopsies. No treatment data are given.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:26:09 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Kissel-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:26:09 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective and follow-up study of consecutive cases with non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:22:52 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Lee-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:22:52 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective and follow-up study of consecutive cases with non-systemic vasculitic neuropathy and microvasculitis in skin biopsies. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:22:58 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Lino-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:22:58 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective and follow-up study of consecutive cases with systemic and non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:23:07 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-L_x00e9_ger-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:23:07 +0000" MODIFIED_BY="Ruth Brassington">
<P>A clinical and electrophysiological study with follow-up of consecutive cases with vasculitic neuropathy, including non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:48:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mathew-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:48:19 +0100" MODIFIED_BY="[Empty name]">
<P>A retrospective study of consecutive cases with systemic and non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:47:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murthy-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:47:53 +0100" MODIFIED_BY="[Empty name]">
<P>A study of consecutive cases with non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:26:17 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Prayson-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:26:17 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective and follow-up study of consecutive cases with muscle vasculitis, some of whom also had sural nerve vasculitis and non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:26:22 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Prayson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:26:22 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective and follow-up study of consecutive cases with sural nerve vasculitis, including non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-29 11:28:20 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Restrepo-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-29 11:28:20 +0100" MODIFIED_BY="Ruth Brassington">
<P>A retrospective study of consecutive cases with non-systemic lymphocytic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:47:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Said-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:47:16 +0100" MODIFIED_BY="[Empty name]">
<P>A clinicopathological study of consecutive cases with vasculitic neuropathy. Treatment is not addressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:24:03 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Seo-JH-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:24:03 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective and follow-up study of consecutive cases with sensory vasculitic neuropathy, including non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:24:08 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Singhal-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:24:08 +0000" MODIFIED_BY="Ruth Brassington">
<P>A clinicopathological and follow-up study of consecutive cases with vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:24:14 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Sobue-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:24:14 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective clinicopathological study of cases with migrating sensory neuritis, some with non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:46:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sugiura-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:46:20 +0100" MODIFIED_BY="[Empty name]">
<P>A clinicopathological study of consecutive cases with non-systemic vasculitic neuropathy. Treatment is not addressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:46:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vincent-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:46:12 +0100" MODIFIED_BY="[Empty name]">
<P>A retrospective study of consecutive cases with microvasculitis of peripheral nerves and muscle, including non-systemic vasculitis. Treatment is not addressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:24:29 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Vrancken-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:24:29 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective and follow-up study of consecutive cases with vasculitic neuropathy, including non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-05 11:24:34 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Weisshaar-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-05 11:24:34 +0000" MODIFIED_BY="Ruth Brassington">
<P>A retrospective and follow-up study of cases with non-systemic vasculitic neuropathy. Treatment was open and uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-17 18:45:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zivkovic-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-17 18:45:54 +0100" MODIFIED_BY="[Empty name]">
<P>A retrospective study of consecutive cases with vasculitic neuropathy, including isolated peripheral nerve vasculitis. Treatment is not addressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-05-17 20:37:23 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-07-05 10:53:58 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-07-05 10:53:58 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-11-05 11:26:58 +0000" MODIFIED_BY="Ruth Brassington">Treatment efficacy in follow-up studies of consecutive patients with non-systemic vasculitic neuropathy</TITLE>
<TABLE COLS="6" ROWS="26">
<TR>
<TH VALIGN="TOP">
<P>Study</P>
</TH>
<TH VALIGN="TOP">
<P>Treatment regimen</P>
</TH>
<TH VALIGN="TOP">
<P>Follow-up duration</P>
</TH>
<TH VALIGN="TOP">
<P>% Follow-up</P>
</TH>
<TH VALIGN="TOP">
<P>N treated</P>
</TH>
<TH VALIGN="TOP">
<P>Outcome</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Collins-2003" TYPE="STUDY">Collins 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Any</P>
</TD>
<TD VALIGN="TOP">
<P>Median 63 (6 to 260) months; 40 patients with at least 2 years follow-up</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>48</P>
</TD>
<TD VALIGN="TOP">
<P>Kaplan-Meier 5-year survival 87%. No additional benefit of intravenous pulse methylprednisolone. Final outcome: 5 asymptomatic, 27 walking independently, 7 ambulant with walking aids, 1 non-ambulatory; median change Rankin disability score -1.0 (-3.0 to 3.0), median change MRC sum score 4.3 (-24 to 16)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Initial oral prednisolone (40 - 100 mg/day for 2 weeks followed by tapering), intravenous pulse methylprednisolone (1 g/day for 3 - 6 days), or both)</P>
</TD>
<TD VALIGN="TOP">
<P>Median 51 (2 to 172) months</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>Initial response rate 17/28 (61%). Final outcome: 16/28 (57%) improved Rankin disability score; median change Rankin disability score -1.0 (-3.0 to 3.0), median change MRC sum score 3.3 (-24 to 16); 19/27 (70%) chronic pain; 18/48 (38%) severe adverse events</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Initial corticosteroids (as above) + oral cyclophosphamide 100 - 150 mg/day</P>
</TD>
<TD VALIGN="TOP">
<P>Median 76 (4 to 221) months</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>Initial response rate 17/18 (94%). Final outcome: 15/18 (83%) improved Rankin disability score; median change Rankin disability score -1.0 (-3.0 to 2.0), median change MRC sum score 7.5 (0 to 10); 9/18 (50%) chronic pain; 22/25 (88%) severe adverse events with discontinuation in 10/25 (40%) patients</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Initial corticosteroids (as above) + azathioprine or intravenous immunoglobulin (dosages not given)</P>
</TD>
<TD VALIGN="TOP">
<P>Median 134 (8 to 260)</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>Initial response rate 2/2 (100%). Final outcome: 2/2 (100%) improved Rankin disability score; median change MRC sum score 1.0 (0 to 2.0); 1/2 (50%) chronic pain</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Davies-1996" TYPE="STUDY">Davies 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Any</P>
</TD>
<TD VALIGN="TOP">
<P>Median 35 (3 to 100) months</P>
</TD>
<TD VALIGN="TOP">
<P>92%</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>Kaplan-Meier 5-year survival 96%. Final outcome: 20/23 (87%) ambulant and self-caring without walking aids; median change Prineas disability score -1.0 (-3.0 to 3.0). Combination therapy used in more severe cases</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Oral corticosteroids (low dosage &lt; 0.5 mg/kg/day, or high dosage &gt; 0.5 mg/kg/day)</P>
</TD>
<TD VALIGN="TOP">
<P>Median 30 (15 to 100) months</P>
</TD>
<TD VALIGN="TOP">
<P>92%</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: 5/11 (45%) improved Prineas disability score; median change Prineas disability score 0 (-3.0 to 0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Corticosteroids (as above) + cyclophosphamide (mostly high-dose intravenous pulses, but some patients chronic low-dose oral therapy)</P>
</TD>
<TD VALIGN="TOP">
<P>Median 39 (3 to 92) months</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: 5/6 (83%) improved Prineas disability score; median change Prineas disability score -1.5 (-3.0 to 0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Corticosteroids (as above) + azathioprine or methotrexate (dosages not given)</P>
</TD>
<TD VALIGN="TOP">
<P>Median 28 (8 to 46) months</P>
</TD>
<TD VALIGN="TOP">
<P>86%</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: 5/6 (83%) improved Prineas disability score; median change Prineas disability score -1.0 (-3.0 to 0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dyck-1987" TYPE="STUDY">Dyck 1987</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Oral prednisolone (dosage not given)</P>
</TD>
<TD VALIGN="TOP">
<P>Not given</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>Unknown</P>
</TD>
<TD VALIGN="TOP">
<P>Survival 85% (17/20). Resolution of deficits from involved nerves was not more rapid in treated patients compared to non-treated patients. Final outcome: 12/17 (71%) ambulant independently, 4/17 (24%) ambulant with walking frame, 1/17 (6%) non-ambulant; 5/17 (29%) improved</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Murthy-1998" TYPE="STUDY">Murthy 1998</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Corticosteroids (no specification given)</P>
</TD>
<TD VALIGN="TOP">
<P>Not given</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: good</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Corticosteroids + cyclophosphamide (no specification given)</P>
</TD>
<TD VALIGN="TOP">
<P>Not given</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: bilateral mild claw hand</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Restrepo-2009" TYPE="STUDY">Restrepo 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Corticosteroids + azathioprine in all patients, additional intravenous pulse cyclophosphamide in 2 patients</P>
</TD>
<TD VALIGN="TOP">
<P> 24 months</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>At six months: remission of symptoms without neurological sequelae in 5/6 (83%), severe course with neurological deficits in 1/6 (17%).</P>
<P>Final outcome after 24 months follow up: quiescent disease in all (100%). </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Seo-JH-2004" TYPE="STUDY">Seo JH 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Any</P>
</TD>
<TD VALIGN="TOP">
<P>Median 60 (24 to 120) months</P>
</TD>
<TD VALIGN="TOP">
<P>83%</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: 2/4 (50%) improved</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Oral prednisone (no dosage given)</P>
</TD>
<TD VALIGN="TOP">
<P>24 months</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: improved</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Oral prednisone (as above) + cyclophosphamide (no specification given)</P>
</TD>
<TD VALIGN="TOP">
<P>Median 84 (48 to 120) months</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: 0/2 (0%) improved</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Oral prednisone (as above) + azathioprine (no dosage given)</P>
</TD>
<TD VALIGN="TOP">
<P>72 months</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: improved</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>24 months</P>
</TD>
<TD VALIGN="TOP">
<P>50%</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: no progression</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Mathew-2007" TYPE="STUDY">Mathew 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Any</P>
</TD>
<TD VALIGN="TOP">
<P>Median 34 months (minimum 12 months)</P>
</TD>
<TD VALIGN="TOP">
<P>91%</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: good (independent functioning in activities of daily living) and remission (partial or complete recovery of the peripheral neuropathy i.e. absence of symptoms or a stable state of at least four weeks without deterioration-consistent with scarring) in all but one (outcome unknown), relapse (new manifestation of peripheral nerve lesion on examination or recurrence or worsening of neurological symptoms following remission or stabilisation for at least four weeks) in two</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Oral prednisolone only (initial doses 40-100mg/day)</P>
</TD>
<TD VALIGN="TOP">
<P>Minimum 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: good and remission in all, relapse in two</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Oral prednisolone as above in combination with oral or intravenous pulsed cyclophosphamide (no further details given)</P>
</TD>
<TD VALIGN="TOP">
<P>Minimum 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>67%</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: good and remission in all but one (outcome unknown)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>Minimum 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: good and remission</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Weisshaar-2002" TYPE="STUDY">Weisshaar 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Any</P>
</TD>
<TD VALIGN="TOP">
<P>Median 24 (0.5 to 144) months; 6 patients with at least 2 years follow-up</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: moderate to good improvement and remission in 8/11 (72%), relapse in 1/11 (9%), no improvement in 1/11 (9%), little improvement in 1/11 (9%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Oral prednisolone only (initial doses 60 -250mg/day)</P>
</TD>
<TD VALIGN="TOP">
<P>Median 25.5 (0.5 to 144) months</P>
</TD>
<TD VALIGN="TOP">
<P>45%</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: moderate to good improvement and remission in 3/5 (60%), relapse in 1/5 (20%). Outcome unknown in 1/5 ( only 2 weeks follow-up)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Oral prednisolone (as above) + intravenous pulsed cyclophosphamide (1g/month)</P>
</TD>
<TD VALIGN="TOP">
<P>24 months</P>
</TD>
<TD VALIGN="TOP">
<P>9%</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: moderate improvement and remission</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Oral prednisolone (as above) + oral azathioprine (125-150mg/day)</P>
</TD>
<TD VALIGN="TOP">
<P>Median 30 (3 to 60) months</P>
</TD>
<TD VALIGN="TOP">
<P>36%</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>Final outcome: moderate to good improvement and remission in 3/4 (75%), little improvement 1/4 (25%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-08-10 15:33:35 +0100" MODIFIED_BY="Ruth Brassington">
<APPENDIX ID="APP-01" MODIFIED="2011-08-10 15:29:20 +0100" MODIFIED_BY="Ruth Brassington" NO="1">
<TITLE MODIFIED="2011-07-06 12:18:06 +0100" MODIFIED_BY="Ruth Brassington">Cochrane Central Register of Controlled Trials (The Cochrane Library) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-10 15:29:20 +0100" MODIFIED_BY="Ruth Brassington">
<P>"non-systemic vasculitic neuropathy" OR "nonsystemic vasculitic neuropathy"</P>
<P>
<B>OR</B>
</P>
<P>("non-systemic vasculitis" OR "nonsystemic vasculitis") AND (neuropath* OR mononeuropath* OR polyneuropath* OR "mononeuritis multiplex" OR "multiple mononeuropath*" OR nerve* OR muscle* OR "peripheral nervous system")</P>
<P>
<B>OR</B>
</P>
<P>(vasculitis OR vasculitic) AND (neuropath* OR mononeuropath* OR polyneuropath* OR "mononeuritis multiplex" OR "multiple mononeuropath*" OR nerve* OR muscle* OR "peripheral nervous system")</P>
<P>
<B>OR</B>
</P>
<P>(vasculitis AND (isolated OR limited OR restricted)) AND (neuropath* OR mononeuropath* OR polyneuropath* OR "mononeuritis multiplex" OR "multiple mononeuropath*" OR nerve* OR muscle* OR "peripheral nervous system")</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-08-10 15:30:32 +0100" MODIFIED_BY="Ruth Brassington" NO="2">
<TITLE MODIFIED="2011-07-06 12:18:47 +0100" MODIFIED_BY="Ruth Brassington">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-10 15:30:32 +0100" MODIFIED_BY="Ruth Brassington">
<P>
<B>#17</B>
</P>
<P>#16 Limits: Publication Date from 1980</P>
<P>
<B>#16</B>
</P>
<P>#15 OR #11 AND #10</P>
<P>
<B>#15</B>
</P>
<P>#12 OR #13 AND #14</P>
<P>
<B>#14</B>
</P>
<P>neuropathy OR neuropathies OR nerve OR nerves OR mononeuropathy OR mononeuropathies OR polyneuropathy OR polyneuropathies OR mononeuritis multiplex OR peripheral nervous system OR muscle vasculitis OR muscular vasculitis</P>
<P>
<B>#13</B>
</P>
<P>vasculitis OR vasculitic OR angiitis OR angeitis</P>
<P>
<B>#12</B>
</P>
<P>nonsystemic vasculitis OR non-systemic vasculitis OR non systemic vasculitis OR 'nonsystemic vasculitis' OR 'non-systemic vasculitis' OR 'non systemic vasculitis'</P>
<P>
<B>#11</B>
</P>
<P>nonsystemic vasculitic neuropathy OR non systemic vasculitic neuropathy OR non systemic vasculitic neuropathy</P>
<P>
<B>#10</B>
</P>
<P>#8 NOT #9</P>
<P>
<B>#9</B>
</P>
<P>animal[all] NOT human</P>
<P>
<B>#8</B>
</P>
<P>#6 AND #7</P>
<P>
<B>#7</B>
</P>
<P>treatment outcome[mh] OR drug therapy[all]</P>
<P>
<B>#6</B>
</P>
<P>#1 OR #2 OR #5</P>
<P>
<B>#5</B>
</P>
<P>#3 AND #4</P>
<P>
<B>#4</B>
</P>
<P>placebo* OR random* OR mask* OR dumm* OR control OR volunteer OR trial</P>
<P>
<B>#3</B>
</P>
<P>controlled clinical trial[all] OR clinical trial[all] OR cross-over study[all] OR single-blind[all] OR double-blind[all] OR review[pt] OR meta-analysis[all] OR multi-center study[all] OR comparative study[all] OR intervention study[all] OR systematic review[all] OR evidence based treatment[all] OR evidence based medicine[all]</P>
<P>
<B>#2</B>
</P>
<P>random allocation[all]</P>
<P>
<B>#1</B>
</P>
<P>randomized controlled trial[all]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-08-10 15:31:41 +0100" MODIFIED_BY="Ruth Brassington" NO="3">
<TITLE MODIFIED="2011-07-06 12:19:00 +0100" MODIFIED_BY="Ruth Brassington">EMBASE (Embase.com) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-10 15:31:41 +0100" MODIFIED_BY="Ruth Brassington">
<P>
<B>#22 </B>
</P>
<P>#12 AND #20 AND [1980-2011]/py</P>
<P>
<B>#21 </B>
</P>
<P>#12 AND #20</P>
<P>
<B>#20 </B>
</P>
<P>#13 OR #16 OR #19</P>
<P>
<B>#19 </B>
</P>
<P>#17 AND #18</P>
<P>
<B>#18 </B>
</P>
<P>#14 OR #15</P>
<P>
<B>#17 </B>
</P>
<P>neuropathy OR neuropathies OR mononeuropathy OR mononeuropathies OR polyneuropathy OR polyneuropathies OR 'mononeuritis multiplex' OR 'multiple mononeuropathy' OR 'multiple mononeuropathies' OR 'peripheral nervous system' OR 'peripheral nerve disease'</P>
<P>
<B>#16 </B>
</P>
<P>'nerve vasculitis' OR 'muscle vasculitis'</P>
<P>
<B>#15 </B>
</P>
<P>'vasculitis'/mj OR vasculitis:de,lnk,cl,ab,ti OR vasculitic</P>
<P>
<B>#14 </B>
</P>
<P>'non-systemic vasculitis' OR 'nonsystemic vasculitis'</P>
<P>
<B>#13 </B>
</P>
<P>'non-systemic vasculitic neuropathy' OR 'nonsystemic vasculitic neuropathy'</P>
<P>
<B>#12 </B>
</P>
<P>#10 NOT #11</P>
<P>
<B>#11 </B>
</P>
<P>'nonhuman'/exp NOT 'human'/exp</P>
<P>
<B>#10 </B>
</P>
<P>#8 AND #9</P>
<P>
<B>#9 </B>
</P>
<P>'drug therapy':de,lnk,cl</P>
<P>
<B>#8 </B>
</P>
<P>#1 OR #7</P>
<P>
<B>#7 </B>
</P>
<P>#5 AND #6</P>
<P>
<B>#6 </B>
</P>
<P>#2 OR #3 OR #4</P>
<P>
<B>#5 </B>
</P>
<P>'placebo'/syn OR dummy OR sham OR random*</P>
<P>
<B>#4 </B>
</P>
<P>'meta-analysis' OR 'multicenter study' OR 'multicenter trial'/syn OR 'controlled study'/syn OR 'clinical trial'/syn OR 'clinical study'/syn OR 'review'/syn OR 'systematic review'/syn</P>
<P>
<B>#3 </B>
</P>
<P>'crossover procedure'/syn OR 'comparative effectiveness'/syn OR 'factorial design'/syn OR 'single blind procedure'/syn OR 'double blind procedure'/syn OR 'triple blind procedure'/syn OR 'study design'/syn</P>
<P>
<B>#2 </B>
</P>
<P>'controlled clinical trial'/syn</P>
<P>
<B>#1 </B>
</P>
<P>'randomized controlled trial'/syn</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2011-08-10 15:33:35 +0100" MODIFIED_BY="Ruth Brassington" NO="4">
<TITLE MODIFIED="2011-07-06 12:19:13 +0100" MODIFIED_BY="Ruth Brassington">Web of Science (ISI Web of Knowledge) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-08-10 15:33:35 +0100" MODIFIED_BY="Ruth Brassington">
<P>
<B>#15</B>
</P>
<P>#14 AND #10 <I>Databases=SCI-EXPANDED, CPCI-S Timespan=1980-2011</I>
</P>
<P>
<B>#14</B>
</P>
<P>#13 AND #12</P>
<P>
<B>#13</B>
</P>
<P>TS=(neuropathy) OR TS=(neuropathies) OR TS=(nerve*) OR TS=(mononeuropathy) OR TS=(mononeuropathies) OR TS=(polyneuropathy) OR TS=(polyneuropathies) OR TS=(mononeuritis multiplex) OR TS=(peripheral nervous system) OR TS=(muscle vasculitis) OR TS=(muscular vasculitis)</P>
<P>
<B>#12</B>
</P>
<P>TS=(vasculitis) OR TS=(vasculitic) OR TS=(angiitis) OR TS=(angeitis)</P>
<P>
<B>#11</B>
</P>
<P>TS=(nonsystemic vasculitic neuropathy) OR TS=(non systemic vasculitic neuropathy) OR TS=(non systemic vasculitic neuropathy)</P>
<P>
<B>#10</B>
</P>
<P>#8 NOT #9</P>
<P>
<B>#9</B>
</P>
<P>TS=(animal) NOT TS=(human)</P>
<P>
<B>#8</B>
</P>
<P>#7 OR #6 OR #5 OR #1</P>
<P>
<B>#7</B>
</P>
<P>#4 AND #3</P>
<P>
<B>#6</B>
</P>
<P>#4 AND #2</P>
<P>
<B>#5</B>
</P>
<P>#3 AND #2</P>
<P>
<B>#4</B>
</P>
<P>TS=(placebo*) OR TS=(blind*) OR TS=(control*) OR TS=(mask*) OR TS=(dumm*) OR TS=(random*)</P>
<P>
<B>#3</B>
</P>
<P>TS=(trial) OR TS=(study) OR TS=(treatment) OR TS=(therapy)</P>
<P>
<B>#2</B>
</P>
<P>TS=(crossover) OR TS=(cross-over) OR TS=(systematic review) OR TS=(meta-analysis) OR TS=(evidence based medicine) OR TS=(evidence based treatment) OR TS=(multi-center study) OR TS=(comparative study) OR TS=(intervention study)</P>
<P>
<B>#1</B>
</P>
<P>TS=(randomi* trial) OR TS=(randomi* study) OR TS=(randomi* treatment) OR TS=(randomi* therapy) OR TS=(random allocation)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>